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The objective of this study was to determine the feasibility of targeting low-normal 
or high-normal arterial carbon dioxide tension (PaCO2), normoxia or moder-
ate hyperoxia, and low-normal or high-normal mean arterial pressure (MAP) in 
comatose patients after out-of-hospital cardiac arrest (OHCA) and successful resus-
citation. In addition, we assessed the e ects of the two di erent levels of PaCO2, 
arterial oxygen tension (PaO2) and MAP on markers of neurological and myocar-
dial injury, cerebral oxygenation, and epileptic activity. Moreover, we investigated 
the association between cerebral oxygenation and the extent of cerebral injury as 
assessed with markers of brain injury and neurological outcome.
Materials and methods
In the Carbon dioxide, Oxygen and Mean arterial pressure After Cardiac Arrest 
and REsuscitation (COMACARE) trial with 23 factorial design, 123 patients resus-
citated from OHCA with a shockable initial rhythm were randomly assigned to 
targeting low-normal (4.5–4.7 kPa) or high-normal (5.8–6.0 kPa) PaCO2, normoxia 
(PaO2 10–15 kPa) or moderate hyperoxia (PaO2 20–25 kPa), and low-normal (65-75 
mmHg) or high-normal (80-100 mmHg) MAP during the rst 36 h in the intensive 
care unit. The primary outcome was the serum concentration of neuron-speci c 
enolase (NSE) at 48 h after cardiac arrest (CA). Secondary endpoints included NSE 
concentrations at 24 and 72 h after CA; S100 calcium-binding protein B (S100B) 
and cardiac troponin T (TnT) concentrations at 24, 48, and 72 h after CA; clin-
ically signi cant changes in continuous electroencephalography (EEG), results of 
frontal regional oxygen saturation (rSO2) measured with near-infrared spectroscopy 
(NIRS) during the rst 48 h of intensive care; and neurologic outcome at 6 months 
(Studies II-III).
In a post hoc analysis, we evaluated the association between frontal rSO2 and NSE 
concentration at 48 h, and the association between frontal rSO2 and good (Cerebral 
Performance Category [CPC] 1-2) and poor (CPC 3-5) neurological outcome (Study 
IV). In another post hoc analysis, we combined data from a subgroup of patients 
with acute myocardial infarction (AMI) and vasopressor dependent hypotension 
with data from a comparable subgroup of another trial (Neuroprotect) to evaluate 
the association between MAP and myocardial injury assessed with the area under 
the 72-hour TnT curve (Study V).
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Main results
We observed a clear separation between the study groups in PaCO2, PaO2, and MAP 
during the 36-hour intervention period. However, there was no di erence in serum 
NSE concentrations between the intervention groups at any of the studied time 
points. S100B and TnT concentrations, EEG ndings, and neurological outcome at 
6 months were comparable between the groups.
High-normal PaCO2 and moderate hyperoxia signi cantly increased frontal 
rSO2, but MAP level did not. No signi cant association between frontal rSO2 and 
NSE or neurological outcome was observed. In a subgroup of patients with AMI and 
vasopressor dependent hypotension, combined from the two trials (COMACARE 
and Neuroprotect), myocardial injury was signi cantly lower in patients assigned to 
the higher MAP group. The risk of new-onset CA or arrhythmias was not increased 
despite signi cantly higher doses of noradrenaline and dobutamine in the higher 
MAP group.   
Conclusions
Targeting low-normal or high-normal PaCO2, normoxia or moderate hyperoxia, 
and low-normal or high-normal MAP was feasible in comatose patients after OHCA 
and successful resuscitation. None of the studied interventions a ected the extent of 
the developing brain damage as measured with biomarkers of neurological injury. 
High-normal PaCO2 and moderate hyperoxia resulted in increased cerebral oxygen-
ation, but this was not associated with the extent of brain injury. In patients with 
AMI and vasopressor dependent hypotension, targeting a MAP between 80/85-100 





Out-of-hospital cardiac arrest (OHCA) is a major cause of morbidity and mortality 
worldwide and causes millions of premature deaths every year 1. Although the over-
all survival of OHCA patients is relatively low and has remained more or less stable 
over the years, the prognosis of witnessed OHCA with a shockable initial rhythm 
and presumed cardiac origin has improved signi cantly during the last decade. 
According to the latest reports in Finland, about a third of these patients were alive 
one year after the event, and in metropolitan areas the one-year survival rate was 
as high as 54% 2. Nine out of ten survivors reached good neurological recovery and 
were living independent lives one year after cardiac arrest (CA) 3.
Several pre-hospital factors have probably contributed to the better prognosis 
of OHCA patients 4. These include improved public awareness, increased bystander 
cardiopulmonary resuscitation (CPR) skills, e cient emergency medical service 
(EMS) systems, focus on high-quality CPR, and reduced delays from collapse to 
de brillation. After return of spontaneous circulation (ROSC), most OHCA patients 
su er from a systemic ischaemia-reperfusion injury, hypoxic ischaemic enceph-
alopathy (HIE), and myocardial dysfunction. Together, these pathophysiological 
processes form the post-cardiac-arrest syndrome, causing signi cant mortality and 
morbidity in resuscitated patients 5. In contrast to the pre-hospital phase, e cient 
post-ROSC interventions are scarce, and targeted temperature management (TTM) 
is the only therapy that has been proved to improve outcomes and implemented in 
clinical practice 6-8. Inhaled xenon seems to attenuate myocardial injury and white 
matter damage in the brain, but its e ect on outcome remains unde ned 9,10. In 
OHCA patients with acute coronary occlusion, early reperfusion with percutaneous 
coronary intervention (PCI) has been suggested to be bene cial but the evidence 
remains inconclusive 11. 
Brain injury caused by HIE is the major cause of death and disability after suc-
cessful resuscitation from OHCA 12. Initially, the developing neurological damage 
is thought to be related to a global ischaemia-reperfusion injury and an increase 
in reactive oxygen species (ROS), which may increase the oxidative damage to the 
brain 13. Subsequently, this is followed by cerebral hypoperfusion, possibly caused 
by increased vasoconstriction during the rst 72 h of post-resuscitation care, further 
aggravating the developing brain injury 14. Arterial carbon dioxide tension (PaCO2), 
arterial oxygen tension (PaO2), and arterial pressure all a ect cerebral oxygen deliv-
ery when the autoregulation of cerebral blood ow (CBF) is disturbed because of 
HIE. In unconscious, mechanically ventilated patients, PaCO2, PaO2, and blood 
pressure can be modi ed via ventilator settings or vasoactive drug infusions, and 
it is reasonable to think that by optimising their levels during the rst days after 
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resuscitation the cerebral hypoperfusion could be prevented and the developing 
brain damage minimised. However, due to the lack of high-quality data, the optimal 
targets of PaCO2, PaO2 and blood pressure remain unknown 15.
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Review of the literature
Out-of-hospital cardiac arrest
The exact incidence of OHCA is unknown. Not all cases are attended or reported by 
EMS, and even the de nition of OHCA can vary regionally. Globally, the incidence 
of EMS-treated OHCA in adult population has been estimated to be approximately 
62 per 100 000 person-years 1. Less than 10% of these patients survive to hospi-
tal discharge, making OHCA a leading cause of mortality worldwide. Geographical 
variation in the incidence of OHCA is extensive, mostly because of di erent cardio-
vascular risk pro les between populations and variation in identifying the cases. The 
regional disparity in outcome is even more pronounced, with a tenfold di erence 
in survival between some areas. This re ects not only the hugely di erent popula-
tion density and response delays between di erent regions, but also the variation in 
public awareness, e ciency of EMS systems, and quality of hospital care 16.
The most common cause of OHCA is ischaemic heart disease, typically present-
ing as a sudden plaque rupture in one of the coronary arteries, leading to thrombus 
formation, coronary occlusion, and abrupt myocardial ischaemia 17,18. Other car-
diac causes of OHCA include cardiomyopathy, valvular heart disease, and congenital 
anatomic and electrical abnormalities, all of which are potential causes of lethal 
arrhythmias. In OHCA patients with cardiac aetiology, the initial rhythm is usually 
ventricular brillation (VF) 19. Without prompt CPR and de brillation, VF slowly 
deteriorates to pulseless electrical activity (PEA) and eventually asystole, reducing 
the chance for survival by approximately 10% per minute 20. The most frequent 
non-cardiac aetiologies of OHCA are trauma, non-traumatic bleeding, pulmonary 
embolism, asphyxia, respiratory failure and hypoxia, metabolic disturbances, and 
intoxication 19. In these conditions the pathophysiological processes behind the 
cardiac arrest (CA) vary widely, and the typical initial rhythm is pulseless electrical 
activity (PEA) or asystole.
Most of OHCA patients with attempted resuscitation by EMS have a cardiac 
cause for the arrest. However, the proportion of VF as initial rhythm has declined 
over the last decades 1, and according to the latest reports in Finland, approximately 
one third of the OHCA patients with attempted resuscitation had a shockable 
initial rhythm 2. At the same time, the incidence of PEA has been increasing 21. 
Improvements in the primary and secondary prevention of coronary artery disease 
and increased use of implantable cardioverter de brillators have probably reduced 
the risk for OHCA with a cardiac aetiology. Because the number of elderly people in 
most western societies is increasing, the overall incidence of OHCA has not declined 
and the proportion of non-shockable initial rhytms is more pronounced than before.
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Known baseline factors a ecting outcome after OHCA include patient age, 
comorbidities, socioeconomic status, the cause of CA, and presenting initial rhythm 
16. Bystander CPR has been found to be the most important intervention associated 
with survival in OHCA patients 4. Other factors with a strong association with out-
come include the delays to CPR and de brillation, the time without compressions 
during advanced life support (ALS), and the delay to ROSC. The chain of survival is 
a concept used to describe the necessary elements needed for successful resuscitation 
20. It consists of early recognition of CA and call for help, rapid activation of the EMS 
system, prompt initiation of bystander CPR, early de brillation, e ective ALS, and 
coordinated post-resuscitation care. Seamless cooperation of the public, emergency 
dispatchers, paramedics, EMS physicians, and hospital sta  is required for the resus-
citation attempt to be successful and the patient to survive. 
After ROSC, many patients remain unconscious for several days after the CA. 
Accurate prognostication during this phase is essential to avoid falsely pessimistic 
prognosis in the individuals who have a chance to recover and, on the other hand, to 
avoid unnecessarily prolonged intensive care in futile situations. Multimodal prog-
nostication strategy combining neurological examination, radiological imaging, 
neurophysiological assessment, and biomarkers is recommended by international 
guidelines 15.
Carbon dioxide and HIE
Carbon dioxide (CO2) is produced in all aerobic organisms as a waste product of cel-
lular respiration 22. In blood, CO2 reacts with water and forms carbonic acid (H2CO3), 
which in turn partly dissociates into bicarbonate (HCO3-) and H+, increasing the 
acidity and lowering the pH of the blood. Changes in CO2 and H+ concentrations 
are sensed by chemosensitive receptors in the carotid body and in the brain, leading 
to some important physiologic changes a ecting the respiratory, cardiovascular and 
central nervous systems of the body. In addition to its crucial role in controlling 
lung ventilation, PaCO2 is a major determinant of CBF 23. Hypercapnia increases 
CBF by increasing arterial pressure and by causing vasodilation in the arterioles and 
precapillary sphincters in the brain. Elevated PaCO2  increases the H+ concentration 
in endothelial cells, leading to activation of voltage-gated K+ channels and hyper-
polarisation of the cell. This reduces intracellular calcium concentration and causes 
smooth muscle relaxation, resulting in vasodilation of the vessel. In patients resus-
citated from CA, the normal autoregulation of CBF is often disturbed due to the 
developing brain injury 24, but the reactivity to changes in PaCO2 remains functional 
even when the autoregulation of CBF is impaired 14.
In addition to its e ect on CBF, CO2 seems to be neuroprotective by several mech-
anisms. Increasing PaCO2 shifts the Hb-O2 dissociation curve to the right, increasing 
the release of oxygen to the tissues and thus, theoretically, facilitating the oxygen 
delivery to the brain 25. Hypercapnia may activate the hypothalamic-pituitary-ad-
renal axis and alter the secretion and function of various brain neurotransmitters, 
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leading to antioxidant and anti-in ammatory e ects 26. Moreover, CO2 has been 
shown to have anticonvulsant properties, and inhaling 5% CO2 has had a potent 
e ect on cortical epileptic activity both in animal models and human epilepsy patients 
27. In experimental models in rats, moderate hypercapnia (PaCO2 8.0–13.3 kPa) has 
been associated with better neurological outcome and less severe histological brain 
damage as compared with normocapnia or severe hypercapnia after global cerebral 
ischemia 28. In contrast, in a recent study with pigs, mild hypercapnia (6.0-6.7 kPa) 
during the rst 4 h after ROSC was associated with higher MAP when compared 
to normocapnia, but there was no di erence in markers of neurological or cardiac 
injury or outcome 29. However, in histological assessment, mild hypercapnia was 
associated with a decrease in neuronal degeneration in the frontal cortex.
Besides the potential bene ts, there are some major risks related to elevated 
PaCO2 levels in comatose CA patients. First, hypercapnia increases CBF and cerebral 
blood volume 22, potentially leading to further increase of intracranial pressure (ICP) 
in patients already su ering from cerebral oedema caused by HIE. Second, hypoven-
tilation and hypercapnia aggravate acidosis, which is in turn associated with poor 
neurological outcome after CA 30. Hypercapnic acidosis may cause vasoconstric-
tion of the pulmonary blood vessels, leading to right ventricular systolic overload. 
Third, acute hypercapnia impairs myocardial function 22. In patients with severe 
acute respiratory distress syndrome (ARDS), acidosis and hypercapnia have been 
associated with impaired right ventricular function and hemodynamic instability 31.
The results of several human studies regarding di erent PaCO2 levels in resus-
citated patients have supported the idea that hypercapnia could be bene cial after 
CA (Table 1). In a large Australian cohort study, 16 542 CA patients were classi-
ed to hypocapnia, normocapnia or hypercapnia according to a single arterial blood 
gas (ABG) analysis during the rst 24 h of ICU care. As compared with normocap-
nia, hypocapnia was associated with poor outcome but hypercapnia was associated 
with comparable mortality with a higher chance of being discharged home among 
survivors 32. In a prospective observational study of 409 Finnish OHCA patients, 
hypercapnia was associated with good neurological outcome at 12 months 33. Before 
the present study, only one randomised trial comparing di erent PaCO2 levels in CA 
patients has been completed. In this study, targeting mild hypercapnia (6.7– 7.3 kPa) 
instead of normocapnia in 83 CA patients during the rst 24 h of intensive care unit 
(ICU) care attenuated the increase of neuron-speci c enolase (NSE) and S100 cal-
cium-binding protein B (S100B) concentrations over time, supporting the possible 
protective e ect of CO2 against neurological injury 34. Moreover, no adverse e ects 
related to mild hypercapnia were reported. Recently, in another prospective cohort 
study of 280 CA patients, the probability for good neurological outcome at hospital 
discharge increased as PaCO2 during the rst six hours after ROSC increased up to 
9.1 kPa 35.
At the same time, however, many studies have reported contradicting results, 
suggesting that hypercapnia is detrimental during the post-resuscitation phase. In 
two consecutive prospective cohort studies carried out at the same university hospi-
tal in the United States, the PaCO2 results of 75 and 193 CA patients during the rst 
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Table 1  Previous studies investigating the association between PaCO2 and 
outcome after cardiac arrest
Study N:o of patients Study design Main findings
Moon 
2007
44 IHCA Prospective cohort 
study, single centre








Hypercapnia was independently associated 








Hypercapnia was associated with similar 
hospital mortality but higher rate of 








Hypercapnia was not associated with 








Normocapnia was associated with good 
neurological outcome at hospital discharge 




409 OHCA Prospective cohort 
study, multicentre
Hypercapnia was associated with good 12-












5 258 OHCA Retrospective cohort 
study, multicentre
PaCO2 had an independent U-shaped 
relationship with hospital mortality
Wang 
2015
550 IHCA Retrospective cohort 
study, single centre
Increasing PaCO2  was inversely associated 
with good neurological outcome
Eastwood 
2016





Serum NSE concentration during the first 72 
h was significantly lower in patients 








Normocapnia was associated with 
increased hospital survival and good 




114 OHCA Retrospective cohort 
study, multicentre
Normocarbia at hospital admission was 
associated with good neurological outcome 
as compared with dyscarbia
Wang 
2017
9 186 OHCA Prospective cohort 
study, multicentre
Hypercapnia was associated with increased 




869 OHCA Post hoc analysis of 
a randomized tiral, 
multicentre
No significant association between PaCO2  








Hypercapnia or hypocapnia during the first 
24 h after hospital admission were not 








Probability for good neurological outcome 
increased as PaCO2 increased up to 9.1 kPa
Abbreviations: PaCO2, arterial carbon dioxide tension; IHCA, in-hospital cardiac arrest; and OHCA, out-of-
hospital cardiac arrest.
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24 h after hospital admission were analysed. The investigators concluded that in both 
studies, hypercapnia was associated with poor neurological outcome at hospital dis-
charge when compared with normocapnia 36,37. A Dutch retrospective cohort study 
of 5 258 mechanically ventilated CA patients found that PaCO2 during the rst 24 h 
after ICU admission had an independent U-shaped relationship with hospital mor-
tality and both hypocapnia and hypercapnia were associated with poor outcome 38. 
Another retrospective cohort study of 550 in-hospital cardiac arrest (IHCA) patients 
from Taiwan reported similar results, concluding that increasing values of the rst 
obtained PaCO2 after ROSC were associated with poor neurological outcome 39. A 
systematic review and meta-analysis of 9 observational studies executed between 
1985 and 2015 stated that both hypocapnia and hypercapnia seem to be detrimental 
when compared with normocapnia after CA 40. More recently, two more observa-
tional studies of 114 and 9 186 OHCA patients, respectively, have reported results 
favouring normocapnia over hypercapnia 41,42. In addition, the results of several 
studies have been neutral, and no association between hypercapnia and mortality or 
neurological outcome has been found 43-47.
Oxygen exposure in resuscitated patients
Adequate oxygen delivery to the tissues is vital during acute conditions such as CA 
48. The brain is particularly susceptible to even short interruptions of oxygen supply. 
During CPR, e cient airway management and ventilation of the lungs are essential 
to achieve ROSC and to prevent secondary hypoxic damage to the brain. For this pur-
pose, current guidelines recommend aiming for maximal fraction of inspired oxygen 
(FiO2) during resuscitation 49. Immediately after ROSC the situation becomes more 
complicated, however, and according to the current recommendations FiO2 should 
be titrated to aim SpO2 94-98% to avoid the potential detrimental e ects of hyper-
oxia 15.
Inadequately high PaO2 after global ischaemia and reperfusion may increase 
the production of ROS 50. They are highly reactive and unstable molecules that are 
known to cause lipid peroxidation, protein oxidation, and DNA damage 13. The 
increased production of ROS can exacerbate the neurological injury after resusci-
tation, and experimental studies in animals have shown that exposure to very high 
levels of PaO2 during the early stages of reperfusion after CA may increase histo-
logical damage to neurons and lead to poor neurological outcome 51. In addition, 
hyperoxia decreases cardiac output (CO) and capillary perfusion, which may further 
account for the possible detrimental e ects of hyperoxia after CA 13.
The e ects of hyperoxia after resuscitation in humans were rst investigated in 
a small randomised trial of 28 OHCA patients who were ventilated with either 30% 
or 100% FiO2 immediately after ROSC (Table 2). The authors observed a statistically 
signi cant increase in NSE within a subgroup of patients exposed to 100% oxygen 
and not treated with TTM at 33 °C, indicating a harmful e ect of extreme hyperoxia 
in patients without the protecting e ect of hypothermia 52. Due to its small size, this 
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Table 2  Previous studies investigating the association between PaO2 and outcome 
after cardiac arrest
Study N:o of patients Study design Main findings
Kuisma 
2006
32 OHCA Randomised trial, 
single centre
FiO2 100% was associated with increased 
NSE at 24 h in patients not treated with TH 
when compared with FiO2 30%
Kilgannon 
2010




PaO2 > 40 kPa in the first ABG analysis in 








Increasing PaO2 during the first 24 h after 
ICU admission was associated with 
















Higher PaO2 during the first 24 h after ICU 




584 OHCA Retrospective cohort 
study, multicentre
PaO2 > 40 kPa was not associated with 
increased in-hospital mortality in OHCA 
patients with VF as the initial rhythm  
Nelskylä 
2013
















792 IHCA Retrospective cohort 
study, multicentre
PaO2 during the first 2 hours after ROSC was 




409 OHCA Prospective cohort 
study, multicentre
No association between hyperoxia exposure 
and neurological outcome at 12 months
Wang 
2014












PaO2 > 40 kPa was associated with 
increased in-hospital mortality, but PaO2 
14-40 kPa was associated with lower SOFA 
score at 24 h
Helmerhorst 
2015
5 258 OHCA Retrospective cohort 
study, multicentre
Hyperoxia was not independently associated 













170 OHCA Retrospective cohort 
study, single centre
PaO2 during the first hour after hospital 




544 OHCA Retrospective cohort 
study, multicentre
PaO2 during the first 48 h after hospital 
admission was not associated with 
neurological outcome at hospital discharge, 
but PaO2 at 12 h was associated with 
increased in-hospital mortality 
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study was not powered to detect di erences in neurological recovery or mortality 
between the groups. Later, two large observational studies using pre-de ned limits 
for hypoxia (PaO2 < 8 kPa), normoxia (PaO2 8-40 kPa), and hyperoxia (> 40 kPa) 
reported con icting results on the e ects of hyperoxia during post-resuscitation 
care. In the rst one, a multicentre cohort study of 6 326 CA patients, hyperoxia 
in the rst ABG analysis obtained in the ICU was independently associated with 
in-hospital mortality when compared with normoxia or hypoxia 53. In further anal-
ysis of the same database, the investigators found a linear relationship between 
increasing PaO2 values over 40 kPa and risk of in-hospital death 54. In the second 
study analysing a multicentre cohort of 12 108 patients, both hyperoxia and hypoxia 
during the rst 24 h of ICU care were associated with increased mortality in compar-
ison to normoxia. However, when illness severity score was taken into account, this 
association was markedly reduced, and the authors concluded that hyperoxia did not 
have a clear and consistent independent relationship with mortality 55.
Later, several observational studies have found a positive association between 
severe hyperoxia (PaO2 > 40 kPa) exposure during early intensive care after CA 
and increased mortality or poor neurological outcome 42,56-58. On the other hand, 
numerous studies have concluded that they were unable to demonstrate that such an 
association exists 33,38,44,59-63. Three systematic reviews and meta-analyses summing 
up the results of the observational studies investigating the relationship between 
hyperoxia and outcomes in CA patients have been published between 2014 and 2018 
64-66. All of them concluded that severe hyperoxia appeared to be associated with 
increased in-hospital mortality. Because of signi cant heterogeneity in the method-
ology and de nitions between the included studies, the authors of all reviews stated 
that the results should be interpreted cautiously and that more research is needed. In 
a recent randomised trial comparing conservative (target SpO2 91-97%) versus usual 
 
Table 2  Continued
Study N:o of patients Study design Main findings
Wang 
2017
9 186 OHCA Prospective cohort 
study, multicentre
PaO2 > 40 kPa during the first 24 h after 
















PaO2 > 40 kPa was associated with poor 
neurological outcome at hospital discharge
Ebner 
2019
869 OHCA Post hoc analysis of 
a randomised trial
No association between hyperoxia exposure 
and neurological outcome at 6 months
Abbreviations: PaO2, arterial oxygen tension; OHCA, out-of-hospital cardiac arrest; IHCA, in-hospital 
cardiac arrest; FiO2, fraction of inspired oxygen; NSE, neuron-specific enolase; TH, therapeutic 
hypothermia; ABG; arterial blood gas; ICU, intensive care unit; VF, ventricular fibrillation; ROSC, return of 
spontaneous circulation; SOFA, sequential organ failure assessment. 
a  The total number of patients analysed includes patients with cardiac arrest, traumatic brain injury, stroke, 
subarachnoid haemorrhage and any mechanical ventilation 
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(target SpO2
no di erence in ventilator-free days or mortality was found between the groups 
67. However, only a minority (17%) of the included participants in this study were 
resuscitated CA patients su ering from HIE.
Based on the literature published so far, it seems that severe hyperoxia is prob-
ably detrimental after CA, but the e ect of moderate hyperoxia (PaO2 15-40 kPa) 
remains unclear. Interestingly, in a prospective observational study of 409 Finnish 
OHCA patients with frequent ABG analyses during the rst 24 h in ICU, the inves-
tigators were unable to detect any harm from hyperoxia exposure and suggested 
that the PaO2 associated with the lowest mortality was around 20 kPa 33. Another 
prospective observational study of 184 patients with repeated ABG samples over 
the rst 24 h concluded that severe hyperoxia (PaO2 > 40 kPa) was associated with 
increased in-hospital mortality, but in contrast, moderate hyperoxia was associated 
with improved organ function at 24 h after CA 57.
Arterial blood gas analysis
The analysis of ABGs refers to the measurement of PaO2, PaCO2, pH, and the oxygen 
saturation of haemoglobin in arterial blood. In critical care, the sample is usually 
obtained via arterial cannula and the analysis is done immediately with a point-of-
care device available in many ICUs. The usual indications for ABG analysis are the 
diagnosis and follow-up of critical conditions that alter gas exchange or acid-base 
balance, and the assessment of oxygenation and ventilation in mechanically venti-
lated patients.
Several factors can alter the results of ABG analysis 68. First, the sample needs 
to be obtained anaerobically into a gas-tight syringe in order to avoid oxygen and 
carbon dioxide entering or leaving the sample. Even small bubbles of air can signi -
cantly alter the PaO2, PaCO2, and pH in the blood. Second, haemolysis in the sample 
can a ect ABG results. As the gradient of PaO2, PaCO2, and pH between plasma 
and red blood cells is not large, this e ect is rarely clinically relevant. Third, in any 
whole blood sample where living cells are interacting with nutrients and oxygen, the 
metabolism can continue. As a result, PaCO2 increases and PaO2 and pH decrease 
over time. This can distort the ABG results if the sample is stored for a long time 
before analysis. Fortunately, this is rarely a problem in modern ICU environment 
because most of the time ABGs are analysed on-site immediately after obtaining the 
sample.
A major issue regarding ABG analyses of resuscitated patients treated with TTM 
is the e ect of temperature on PaO2, PaCO2, and pH. As the temperature of blood 
decreases, the solubility of oxygen and CO2 increase, lowering their partial pressures 
and changing the relationship between partial pressure and the total content of 
oxygen and CO2 in the blood 68. Moreover, because the dissociation of an acid (i.e. 
H2CO3) to the corresponding cation (HCO3-) and H+ is an endothermic reaction 
requiring energy, cooling of the blood will shift the balance of the equilibrium 
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towards H2CO3, reducing the concentration of H+ and increasing the pH 69. Because 
the reference ranges of PaO2, PaCO2, and pH have been de ned in healthy vol-
unteers at 37°C and there is limited knowledge of their normal values in varying 
temperatures, the interpretation of the ABG results in hypothermic patients can be 
challenging. 
Two di erent scienti c models exist to analyse PaCO2 and pH in di erent tem-
peratures: In alpha-stat the results are interpreted at normal body temperature 
(37°C), whereas in pH-stat the temperature is corrected to the patient’s actual tem-
perature 70. Because the complex e ects of temperature on metabolism, circulation, 
and respiration are not fully understood, neither method can be stated to be correct, 
and the choice should be made depending on the clinical situation. From the phys-
iological perspective, correcting pH for temperature may not seem logical because 
the pH of neutrality also changes with temperature. However, during therapeutic 
hypothermia, interpreting PaCO2 values corrected to the patients’ actual tempera-
ture might be more reasonable 71. 
During TTM with a target temperature of 33°C, the PaCO2 measured with pH-stat 
is approximately 10% lower than the PaCO2 measured with alpha-stat 45. This means 
that lower-threshold normocapnia according to alpha-stat would be interpreted as 
clear hypocapnia with pH-stat. At the same time, the metabolic rate of the hypo-
thermic body is reduced, leading to lower CO2 production in the cells and increasing 
the risk for unintentional hypocapnia with conventional ventilator settings. Indeed, 
lower-threshold normoventilation according to temperature non-corrected PaCO2 
has been shown to lead to lower jugular bulb oxygen saturation and increased risk of 
cerebral vasoconstriction and ischemia during TTM 72.
Regarding oxygen, the e ects of cooling are somewhat di erent. In contrast 
with CO2, the amount of oxygen in inspired air and in the alveoli is kept constant 
by adjusting the FiO2 in mechanically ventilated patients 70. The partial pressure 
of oxygen in the alveolar air equilibrates with the partial pressure of oxygen in the 
alveolar capillaries, keeping PaO2 essentially constant despite the lowering tem-
perature and the increasing solubility of oxygen in the blood. At the same time, the 
oxyhaemoglobin dissociation curve is shifted to the left, increasing the a nity of 
haemoglobin to oxygen. Moreover, the decreased metabolic rate during hypother-
mia reduces oxygen consumption in the cells. Altogether, this means that the total 
oxygen content in the blood increases with cooling temperature. Considering the 
dynamics of PaO2 in hypothermic patients, the interpretation of PaO2 level should 
always be made corrected to the actual temperature during TTM in order to main-
tain adequate oxygenation and to avoid desaturation. 
Blood pressure after cardiac arrest
Hemodynamic instability and hypotension are common after CA and resuscita-
tion. They are thought to be the result of various di erent mechanisms related to 
the global ischaemia-reperfusion injury and some other factors. First, myocardial 
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stunning caused by the ischaemia-reperfusion injury can lead to acute myocardial 
dysfunction and low CO 73. Second, resuscitated patients su er from a sepsis-like 
systemic in ammation response syndrome that leads to disturbances in the in am-
matory cascade and increases the levels of various cytokines, causing systemic 
vasodilation and low cardiac lling pressures 74. Third, relative adrenal axis insu
ciency is common in CA patients, further aggravating the haemodynamic instability 
75. Finally, acute coronary syndrome (ACS) is the most common cause of OHCA, 
and many resuscitated patients su er from myocardial ischaemia or acute myocar-
dial infarction (AMI). This can potentially a ect cardiac contractility and lead to 
decreased CO 76.
As a result of the developing brain injury after CA, CBF autoregulation is dis-
turbed and right-shifted in many patients, meaning that CBF may become directly 
dependent on MAP 24. In addition, hypoxia-induced cerebral swelling can increase 
ICP, and together with systemic hypotension this can severely compromise adequate 
cerebral perfusion pressure (MAP minus ICP). Thus, arterial hypotension after CA 
can lead to cerebral hypoperfusion and aggravate the developing brain damage. In 
experimental studies with animals, increasing MAP with vasoactive agents after CA 
has indeed been associated with better outcomes 77.
So far, many observational human studies have found an association between 
post-ROSC hypotension and poor outcome 78-91 (Table 3). In contrast, only one 
study has reported that no association between MAP and outcome was observed 92. 
In a systematic review of 9 observational studies performed between 2008 and 2105, 
higher blood pressure level during the post-resuscitation phase was associated with 
improved neurological outcomes 93. However, most of the studies included both 
OHCA and IHCA patients, and there was marked methodological heterogeneity 
between them. In addition, in most of the studies blood pressure was recorded only 
for a relatively short period of time (6-24 h) after ICU admission. More recently, 
several new studies assessing the relationship between post-ROSC hypotension and 
outcome speci cally in OHCA patients have been published. In a post hoc analysis 
of the TTM trial 8, hypotension (MAP < 65 mmHg) during the rst 36 h in ICU was 
associated with increased 30-day mortality 86. In a prospective multicentre observa-
tional study in Finland, a total of 1.2 million blood pressure values of 412 patients 
measured during the rst 48 h of ICU care were analysed. The authors concluded 
that hypotension during the rst six hours was an independent predictor of poor 
neurologic outcome at one year, but hypotension later during the intensive care 
was not 87. In another small observational study extending the blood pressure mon-
itoring to 96 h after hospital admission, hypotension (MAP < 75 mmHg) was again 
associated with poor outcome91. Interestingly, the authors found that the e ect of 
MAP on outcomes was attenuated with increasing age.
During intensive care, blood pressure can be regulated with uid infusions 
and vasoactive agents. Based on the studies performed so far, it has been hypothe-
sised that targeting a higher MAP during the early post-resuscitation period would 
improve clinical outcomes. However, no randomised trials comparing the e ect of 
two di erent blood pressure levels have been conducted before. Due to the lack of 
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Table 3  Previous studies investigating the association between blood pressure and 
outcome after cardiac arrest
Study N:o of patients Study design Main findings
Kilgannon 
2008
102 OHCA / 
IHCA
Retrospective 
cohort study, single 
centre
Hypotension (SAP < 100 mmHg at least twice) 
within the first 6 h after ROSC was associated 
with higher in-hospital mortality
Trzeciak 
2009





Hypotension (SAP < 90 mmHg) within 1 h 




73 OHCA Retrospective 
cohort study, single 
centre
Hypotension (SAP < 90 mmHg or MAP < 60 
mmHg) within the first 24 after ROSC was 
associated with higher in-hospital mortality
Beylin 
2013




Lower MAP during the first 24 h after ROSC 
was associated with increased in-hospital 
mortality; increasing use of vasoactive agents 
was associated with increased mortality and 
lower CPC scores 
Kim 
2013
4 617 IHCA Prospective cohort 
study, multicentre
Lowest MAP at 24 h after ICU admission was 
associated with in-hospital mortality 
Bray 
2014
3 620 OHCA Prospective cohort 
study, multicentre
Hypotension (SAP < 90 mmHg) at hospital 
arrival was associated with higher in-hospital 








Time-weighted average MAP during the first 6 
h after ROSC was associated with good 
neurological outcome at hospital discharge
Ameloot 
2015




MAP between 76-86 mmHg during the first 24 
h in ICU was associated with highest survival
Bhate 
2015
13 150 OHCA / 
IHCA
Systematic review Higher blood pressure post ROSC was 




920 OHCA Post hoc analysis of 
a randomised trial
Hypotension (MAP < 65 mmHg) during the 
first 36 h in ICU was associated with 30-day 
mortality; high dose of vasopressors was an 
independent predictor of 30-day mortality
Young 
2015




No association between MAP during TH and 
neurological outcome was observed
Laurikkala 
2016
412 OHCA Prospective cohort 
study, multicentre
Lowest MAP within 6 h after ROSC was 




122 OHCA Prospective cohort 
study, single centre
Higher mean MAP during the first 96 h of 
hospital admission was associated with 




289 OHCA Retrospective 
cohort study, 
multicentre
Time-weighted average MAP during the first 3 
h after ROSC was associated with survival and 








MAP > 90 mmHg during the first 6 h after 
ROSC was associated with increased in-
hospital survival and better neurological 
outcome as compared with MAP 70-90 
mmHg
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high-quality data, the optimal MAP target remains unknown and current European 
guidelines recommend aiming for a MAP su cient to achieve an adequate urine 
output and decreasing lactate levels 15. In addition, there are concerns regarding the 
potential side e ects of vasoactive and inotropic agents such as noradrenaline and 
dobutamine, and in some of the previous studies, both low MAP and increasing 
use of vasoactive agents has been associated with mortality and poor neurological 
outcome 81,86.
Continuous direct arterial pressure measurement is the standard method of 
blood pressure monitoring in ICU patients. The radial artery is the most common 
site for cannulation, and common alternatives include the brachial artery and the 
femoral artery. Several factors can a ect the reliability of direct blood pressure mon-
itoring and need to be considered when interpreting the results 94. First, under- or 
overdamping of the monitoring system is common. This can cause alterations in 
the arterial pressure waveform and thus a ect the observed blood pressure values. 
Underdamping typically causes systolic pressure overshoot, whereas overdamping 
results in an abnormally blunt waveform and an underestimation of the systolic 
pressure level. Fortunately, in both cases the MAP usually remains relatively accu-
rate despite signi cant deviations in the systolic and diastolic pressures. Minimising 
the length of pressure tubing, limiting the addition of valves and connections to 
the system, and eliminating all air bubbles from the hosing can help to alleviate 
the e ects of under- and overdamping. Second, the monitoring system needs to be 
zeroed, meaning that the zero point of the pressure scale has to be established at 
ambient atmospheric pressure. Failure to do this before the monitoring is begun 
and periodically thereafter can cause bias to the blood pressure results. Third, the 
pressure transducer must be appropriately leveled, setting the zero-reference point 
relative to the patient’s body. In ICU patients, the transducer is usually placed at 
mid-thoracic level, aligning the reference level at the position of the left atrium. 
Because even small deviations of the transducer level can lead to signi cant changes 
in the measured blood pressure, the correct level must be meticulously checked, 
especially after the patient’s position is changed. 
Table 3  Continued
Study N:o of patients Study design Main findings
Russo 
2018
122 OHCA Retrospective 
cohort study, single 
centre
Hypotension (MAP < 75 mmHg) during the 
first 96 h after ICU admission was associated 




657 OHCA Post hoc analysis of 
a randomised trial
MAP during TTM was not associated with NSE 
concentrations or survival
Abbreviations: OHCA, out-of-hospital cardiac arrest; IHCA, in-hospital cardiac arrest; SAP, systolic arterial 
pressure; ROSC, return of spontaneous circulation; ICU, intensive care unit; MAP, mean arterial pressure; 
CPC, Cerebral Performance Category; TH, therapeutic hypothermia; TTM, targeted temperature 
management; NSE, neuron-specific enolase.
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Feasibility of targeting a specific PaCO2, PaO2, and 
MAP level
The main purpose of mechanical ventilation in unconscious and intubated critical 
care patients is to maintain adequate oxygenation of the tissues and remove CO2 
from the body when the patient is unable to breathe spontaneously. Increasing 
the respiratory rate (RR) and/or tidal volume (TV) on the ventilator increases the 
minute ventilation (MV) of the lungs and CO2 clearance from the body, decreas-
ing PaCO2 95. PaO2 can be adjusted by changing FiO2 and by maintaining adequate 
positive end-expiratory pressure (PEEP) that keeps the small airways open and pre-
vents the alveoli from collapsing. Although these relationships between MV and 
PaCO2, and PaO2 and FiO2 seem fairly trivial, there are several factors that can make 
maintaining  adequate ventilation and oxygenation challenging  during intensive 
care. First, in patients with lung injury or ARDS, aiming for normal PaCO2 with 
positive-pressure ventilation can lead to excessive tidal volumes and airway pres-
sures, stretching the lungs and causing iatrogenic damage 96. Second, atelectasis of 
the alveoli can cause signi cant shunting, and lead to persistent hypoxemia that does 
not respond to raising FiO2. Third, mechanical ventilation and general anaesthesia 
change the distribution of both air and blood ow in the lungs, increasing ventila-
tion-perfusion mismatch and leading to derangements in both PaCO2 and PaO2 25. 
Fourth, haemodynamic instability and reduced CO can a ect peripheral tissue and 
lung perfusion, and thus alter the PaCO2 and PaO2 levels. In addition, decreased 
body temperature during TTM slows down the metabolic rate of the body, leading 
to reduced O2 consumption and CO2 production in cells 97.
Despite the recommendations of keeping PaCO2 and PaO2 within the physiologic 
range, deviations of both of these parameters are common after CA. In a retrospec-
tive analysis of 122 OHCA patients with frequent ABG analyses during the rst 48 h 
after hospital admission, normocapnia was maintained in only 55% of the analysed 
samples 98. In a large observational study of more than 16 000 CA patients, about 
20% of the patients had at least one episode of hypocapnia, and about 40% at least one 
episode of hypercapnia during the rst 24 h from ICU admission 32. Derangements 
of both PaCO2 and PaO2 were also common in an observational study of resuscitated 
OHCA patients in Finland 33. In another large observational study of over 6000 CA 
patients, only 19% of them had normoxia in ABG analysis performed within 24 h of 
ICU admission 53. Moreover, in an analysis of an Australian ICU database of more 
than 150 000 critically ill patients, almost half of the mechanically ventilated patients 
were hyperoxaemic at some point during the rst 24 h in ICU 99. Hyperoxia expo-
sure has been shown to be more common in OHCA patients with longer delays from 
collapse to ROSC, and with longer delays from ROSC to ICU admission 60. 
Little data on the feasibility of targeting speci c levels of PaCO2 and PaO2 exist 
so far. A retrospective analysis of 75 CA patients concluded that the prescribed MV 
after ROSC had only a weak correlation with measured PaCO2 soon after ROSC 
37. In a randomised controlled pilot trial comparing mild hypercapnia with normo-
capnia, raising PaCO2 over the normal range by adjusting RR and TV was feasible, 
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and good separation in PaCO2 between the intervention and control groups was 
achieved during the rst 24 h from ICU admission 34. In a before-and-after cohort 
study of 105 mechanically ventilated ICU patients comparing conventional versus 
conservative oxygen therapy, a clear di erence in both FiO2 and PaO2 was observed 
between the groups 100. Later, similar results were observed in another study with 
resuscitated CA patients 101.
Regarding blood pressure, the e ects of noradrenaline and other vasopressors 
are well documented, and adjusting MAP with vasoactive infusions during general 
anaesthesia is part of the daily routine in a myriad of operating rooms all over the 
world 25. Noradrenaline is the vasopressor of choice in shock, and the feasibility of 
goal-directed therapy targeting a speci c MAP range with noradrenaline infusion 
in critical care patients has been demonstrated 102-104. Although no studies assessing 
the feasibility of blood pressure control speci cally in CA patients have been done so 
far, there is little reason to assume that adjusting the MAP after resuscitation would 
be substantially more di cult than in septic or cardiogenic shock patients. However, 
despite the recommendations of the current guidelines to use noradrenaline with 
or without dopamine to maintain adequate MAP after CA 15, hypotension remains 
common during post-resuscitation intensive care, and studies investigating the fea-
sibility of tight blood pressure control in this patient group are needed 105.
Markers of neurological injury
Neuron-specific enolase
NSE is a cytoplasmic glycolytic enzyme found in neurons and neuroectodermal cells 
106. It is released into the cerebrospinal uid and bloodstream after neuronal damage 
and impairment of the blood-brain barrier. After CA, serum concentrations of NSE 
during the rst 24–72 h correlate with the severity of the developing brain injury 
and the probability of a poor outcome 107,108. 
Recent research has further con rmed the value of NSE as a marker of cere-
bral injury after resuscitation. In a post hoc analysis of the Targeted Temperature 
Management trial, Stammet and colleagues analysed a total of 1823 serum samples 
from 686 patients and found NSE to be a strong and robust predictor of outcome in 
CA patients 109. In the largest study investigating NSE as a biomarker of neurolog-
ical injury after CA so far, Streitberger and colleagues analysed the blood samples 
of 1053 OHCA and IHCA patients 110. In line with the previous studies, they found 
that elevated NSE concentration at 72 h after CA was a strong indicator of poor 
outcome. In a recent post hoc analysis of the FINNRESUSCI study, Wihersaari and 
colleagues analysed the blood samples of 249 OHCA patients and found that the abil-
ity of NSE to predict outcome was dependent on both the patients’ age and the delay 
to ROSC 111. They concluded that NSE at 48 h after CA had an excellent predictive 
value in young patients, but in older patients it was remarkably poor. Moreover, the 
longer the time from collapse to ROSC, the better the ability of NSE was to predict 
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outcome. 
Although NSE is a highly speci c marker of neuronal damage, it has some major 
pitfalls. First, no consistently reliable cut-o  values for poor outcome have been 
established in the di erent studies 112. As such, NSE can be used only as part of the 
multimodal prognostication, and clinical decisions should never be based solely on 
NSE results. Serial measurements are probably useful because an increase of NSE 
between any two time points during the rst 72 after CA is strongly associated with 
poor outcome. Second, in addition to neurons, NSE is also produced in peripheral 
neuroendocrine cells. NSE serum concentration may increase considerably in case 
of malignant proliferation of neuroendocrine cells, and it is used as a biomarker in 
the diagnosis, prognosis, and follow-up of malignant neuroendocrine neoplasms, 
most notably small cell lung cancer 113. Very high NSE concentrations due to a neu-
roendocrine tumour have been described in patients with excellent neurological 
recovery after CA 110. Third, substantial amounts of NSE is found in erythrocytes, 
and even mild haemolysis can signi cantly increase its concentration in the blood 
114. Moreover, there is signi cant variation in the measured NSE concentrations 
between di erent assays and laboratories 115. Whether fresh or frozen samples are 
analysed can also a ect the results.
Despite its shortcomings, NSE is the most widely available and best documented 
surrogate marker of brain injury after CA. It is easy to use, and the concentrations 
are not likely to be a ected by sedation or other medications. As such, it has an 
established role in the routine multimodal prognostication of CA patients 116, and its 
use is recommended by the current guidelines 15.
S100 calcium-binding protein B
S100B is a cytoplasmic protein found primarily in astroglial cells 117. Similarly to 
NSE, it is released into the bloodstream in case of brain injury, and its serum con-
centration during the rst days after CA has been shown to have high speci city 
in predicting poor neurological outcome in resuscitated patients 118. Because the 
evidence of S100B in the neuroprognostication of CA patients is less extensive 
compared to NSE, it has been recommended as a secondary marker of neurological 
injury during post-resuscitation care 15. In addition to CA, S100B has been used as 
a marker of traumatic brain injury and blood-brain barrier permeability. Moreover, 
S100B is expressed in melanocytes and chondrocytes, making it a useful marker in 
malignant melanoma and some other neoplasms and occasionally complicating the 
interpretation of high concentrations in the context of CA prognostication. 
Cardiac troponin T
The troponin complex is a protein cluster found in skeletal muscle and cardiac 
muscle cells 119. It consists of three distinct polypeptides: troponin C, troponin T, 
and troponin I. The troponin complex forms a part of the contractile apparatus 
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of the muscle cell and thus has a pivotal role in muscle contraction. Most of the 
troponins are bound to the actin laments in the sarcomeres and bind to myosin 
when the sarcomere contracts. In addition, small amounts of troponins exist in the 
cytoplasm of the muscle cell. While troponin C in cardiac muscle is identical to the 
troponin C in skeletal muscle, troponins I and T in the heart are cardiac speci c. 
When cardiomyocytes are irreversibly damaged, the troponins leak into the blood-
stream and their concentrations in the blood re ect the extent of myocardial cell 
necrosis. Detection of a rise in cardiac troponin level in a blood sample forms the 
foundation of current diagnostics of AMI 120.
In patients with AMI, the cardiac troponin T (TnT) concentration in plasma 
rises sharply and peak level is reached between 4 to 12 h after coronary occlusion. 
In previous studies, single time-point assessments of cardiac troponin levels, as well 
as the area under the 72-hour TnT curve, have correlated strongly with infarct size 
assessed with accurate imaging methods such as single-photon emission comput-
ed tomography (SPECT) or MRI 121. In addition, the troponin measurements at 48 
and 72 h have predicted patient outcome and left-ventricular ejection fraction after 
AMI 122. 
The introduction of more sensitive troponin assays during the past years has 
further enhanced the diagnostic accuracy of ACS 119. At the same time, the pitfalls 
of troponin diagnostics have been highlighted. In patients with impaired renal func-
tion, cardiac troponin levels are often chronically elevated, compromising their 
diagnostic performance in case of an ACS 123. Serial troponin measurements and 
looking for temporal changes can be helpful in this patient group 124. In OHCA 
patients, TnT levels are elevated regardless of the aetiology of the arrest, probably 
due to ventricular arrhythmias and direct myocardial damage during the mechanical 
chest compressions of CPR 125. The TnT level has been independently associated 
with mortality and multi-organ failure after CA 126.
Near-infrared spectroscopy
Near-infrared spectroscopy (NIRS) is a non-invasive technique to assess tissue oxy-
genation. It is based on re ectance spectroscopy of the near-infrared spectrum of 
light (wavelengths 700-1100 nm). Measuring the absorption of light in the tissue 
and using the principles of the Beer-Lambert law, the ratio of oxygenated haemoglo-
bin (Hb) to total Hb and thus the regional oxygen saturation (rSO2) in the tissue can 
be estimated 127. As light in the near-infrared range penetrates biological tissues sev-
eral centimetres, by placing the NIRS sensors on the forehead, the rSO2 in the frontal 
cortex of the brain can be assessed. The changes in frontal rSO2 are considered to 
re ect changes in the relationship between oxygen delivery and consumption in the 
brain 128.
Several issues limit the reliability of NIRS as an indicator of cerebral oxygenation. 
First, the infrared light emitted from frontal NIRS transmitter has to penetrate the 
skin, the skull, and the meninges before reaching the cerebral tissue. Thus, the 
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frontal rSO2 re ects the mean oxygen saturation of not only the brain, but also of 
various other extracerebral tissues 127. Using two separate receivers, one closer to 
the transmitter and the other more far apart, can help to distinguish between super-
cial extracerebral and deeper brain tissue saturation. Second, the e ects of global 
ischaemia and low CBF are not evenly distributed in the brain, and oxygenation 
can vary signi cantly between di erent areas 129. Importantly, some of the regions 
more vulnerable to ischaemia, such as the hippocampus, thalamus and cerebellum, 
are too deeply situated for infrared light to reach them. Therefore, these areas can 
su er from hypoxia even when the oxygenation of the frontal cortex seems ade-
quate. On the other hand, haemorrhage or local ischaemia in the frontal part of the 
brain can result in low frontal rSO2 even if the oxygenation in other regions is not 
disturbed. Third, because of large di erences in frontal rSO2 between individuals, 
no universally accepted reference range for “normal” cerebral oxygenation exists 128. 
Instead, 10-20% deviation from the baseline rSO2 has been suggested to be indicative 
of cerebral hypoxia.
Despite its limitations, the use of NIRS monitoring to optimise cerebral oxy-
genation during surgery and anaesthesia seems to be associated with improved 
neurologic outcomes in a wide variety of surgical procedures 130. In CA patients 
the situation becomes more complicated because the baseline frontal rSO2 and the 
optimal target level are unknown. However, according to a recent review summing 
up the results of 26 di erent studies, higher frontal rSO2 during on-going CPR was 
consistently associated with increased probability of ROSC 131. The authors con-
cluded that monitoring frontal rSO2 during CA could be more helpful in terminating 
futile resuscitation attempts than in predicting favourable outcome.
So far, there are a limited number of studies assessing the role of NIRS during 
post-resuscitation care and prognostication, and the results are somewhat contro-
versial. In a small observational study of 28 OHCA patients treated with TH, the 
induction of hypothermia decreased the frontal rSO2 in all patients, but the decrease 
was greater in patients with poor outcome 132. In a small feasibility study including 
21 patients resuscitated from IHCA or OHCA, the median frontal rSO2 during the 
rst 24 h of ICU care was signi cantly higher in patients surviving to hospital dis-
charge when compared to non-survivors 133. Another study including 60 IHCA/
OHCA patients concluded that patients with good neurological outcome (Cerebral 
Performance Category [CPC] 1-2) at six months had signi cantly higher median 
frontal rSO2 levels during the 40-hour NIRS measurement 134. In a Japanese study, 
frontal rSO2 was measured from 672 OHCA patients at hospital arrival and those 
with good neurological outcome at 90 days had signi cantly higher rSO2 values 135. 
However, only 52 patients (8%) had a sustained ROSC at the time of the rSO2 mea-
surement, and the rest had still on-going CPR. The vast majority of the patients 
(72%) were pronounced dead in the emergency department. 
Interestingly, the authors of a prospective observational study of 43 OHCA 
patients treated with TTM reported that the mean rSO2 during the rst 48 h of ICU 
care was not statistically di erent between patients with good and poor outcome 
(62% ± 6 vs. 58% ± 9, respectively, p = 0.13) 136. In another larger cohort of 107 
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OHCA patients also treated with TTM, the mean frontal rSO2 over 48 h was signi -
cantly higher in patients with good 6-month neurological outcome when compared 
with those with poor outcome (68% ± 4 vs. 66% ± 5, respectively, p = 0.035), but 
the absolute di erence in rSO2 was so small that it is unlikely to have any clinical 
relevance 137.
Electroencephalography in resuscitated patients
Electroencephalography (EEG) is a standard investigation and an important part of 
the multi-modal prognostication in comatose CA patients. 116. However, its value 
in outcome prediction has been limited because of a wide variety of di erent classi-
cation systems used, signi cant inter-rater variability in the interpretation of the 
ndings, and the confounding e ects of sedative drugs commonly administered in 
ICU. Thus, the current guidelines recommend the use of EEG only together with 
other methods of prognostication 15. 
Despite of these limitations, using standardized interpretation, speci c EEG 
patterns have been shown to predict neurological outcome in CA patients very accu-
rately. In a post hoc analysis of the TTM study, the investigators analysed the EEGs 
of 103 patients still comatose at 72 h after CA using a standardized terminology 
proposed by the American Clinical Neurophysiology Society 138. They found that 
highly malignant EEG patterns (burst-suppression or suppressed background with 
or without continuous periodic discharges) predicted poor neurological outcome at 
6 months with 100% speci city and 50% sensitivity 139. Conversely, a benign EEG 
was highly predictive of a good functional outcome. In another prospective cohort 
study, continuous EEG was recorded for at least 72 h in 388 comatose CA patients 
and an unfavourable EEG pattern (isoelectric, low-voltage, or burst-suppression 
with identical bursts) at 24 h was invariably associated with poor neurologic out-
come at 6 months 140. In a recent prospective multicentre prognostication study of 
346 CA patients, malignant EEG (isoelectric or burst-suppression) predicted poor 
outcome again with 100% speci city 141. In addition to its value in outcome predic-
tion, continuous EEG monitoring can be used to detect non-convulsive seizures that 
can potentially cause secondary brain damage in patients with HIE.
Rationale for the current study
A pilot study is a small-scale, preliminary study that is used to test the methods and 
procedures that the investigators are planning to use later on a larger scale. The 
main purpose of a pilot study is to assess the practical and logistical aspects of a 
future full-scale trial and test whether the full study would be feasible or not 142. In 
this way, patient recruitment, the randomisation process, and the feasibility of the 
interventions can be assessed before investing time and resources in a larger trial. 
Another bene t of pilot studies is that they can provide preliminary data regarding 
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the e ects and safety of the studied interventions, and help to generate new hypoth-
eses. For example, investigating the e ects of di erent interventions on biomarkers 
or other non-clinical outcomes in a smaller sample of patients can give a signal of 
bene t or harm that can be further tested in a full-scale trial. 
In critical care, there are several examples of successful pilot trials conducted 
before proceeding to a full-scale study 143. However, pilot studies should not be used 
without awareness of the potential pitfalls. Most of the risks are mainly related to the 
small sample size. Because of this, pilot studies are rarely powered to detect di er-
ences in the e cacy of the studied interventions, and their results regarding clinical 
endpoints may be overinterpreted 144. As a consequence, conducting a full-scale trial 
can be abandoned altogether, and important research questions may remain unan-
swered. Similarly, pilot trials are usually not powered to con dently detect adverse 
e ects related to the interventions, and for this reason, they should not be used for 
the safety assessment of a full study. In addition, because of the small sample size, the 
results of a pilot trial should be used cautiously in the sample size calculations for a 
full-scale trial 145. When interpreting the feasibility results of a pilot study, it should 
be kept in mind that the results obtained in a small number of highly motivated 
centres might be misleading, and the same procedures in di erent critical care envi-
ronments in multiple di erent countries can turn out to be much more challenging.
As mentioned before, PaCO2, PaO2, and MAP are modi able factors that a ect 
cerebral oxygen delivery when the autoregulation of CBF is disturbed in resuscitated 
patients su ering from HIE. The results of previous studies suggest that optimis-
ing the levels of PaCO2, PaO2, and MAP during the rst days after resuscitation 
could mitigate the developing brain injury and have an e ect on patient outcome. If 
proven safe and e ective, this kind of intervention would be easy to implement, and 
the additional costs compared to current practice would be minimal. Because of the 
lack of high-quality data, however, the de nitive targets remain unde ned 15. With 
the current pilot study, we wanted to ll this gap in the knowledge in two ways: 
First, we wanted to test if tight control of PaCO2, PaO2 and MAP during post-re-
suscitation care is feasible in a relatively small sample of patients before planning 
a full-scale trial. Second, we wanted to obtain data on the e ects of these di erent 
levels of PaCO2, PaO2 and MAP on surrogate markers of cerebral and myocardial 
injury, cerebral oxygenation, and epileptic activity to decide whether a larger trial 
with similar interventions would be justi ed, and to identify the interventions that 
would most likely have an e ect on mortality and neurological outcome.
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Aim of the study
The aim of the current study was 
1. To determine the feasibility of targeting low-normal or high-normal PaCO2, 
normoxia or moderate hyperoxia, and low-normal or high-normal MAP in 
comatose patients after OHCA and successful resuscitation (I-III).
2. To assess the e ect of low-normal vs. high-normal PaCO2, normoxia vs. 
moderate hyperoxia, and low-normal vs. high-normal MAP on markers 
of neurological and myocardial injury, cerebral oxygenation, and epileptic 
activity in comatose patients after OHCA and successful resuscitation (II, III, 
and V).
3. To investigate the association between cerebral oxygenation and the extent 
of cerebral injury as assessed with markers of brain injury and neurological 




Study setting and design
Targeting low- or high-normal Carbon dioxide, Oxygen, and Mean arterial pres-
sure After Cardiac Arrest and REsuscitation (COMACARE) was a prospective, 
multi-centre, randomised trial with 23 factorial design. A total of 123 uncon-
scious, mechanically ventilated patients successfully resuscitated after OHCA were 
randomly assigned to targeting low-normal or high-normal PaCO2, normal or mod-
erately elevated PaO2, and low-normal or high-normal MAP for the rst 36 h in the 
ICU. Accordingly, each patient was randomised into one of eight groups, each group 
having a di erent combination of targets for PaCO2, PaO2 and MAP.
A summary of the study characteristics is presented in Table 4. The rst pub-
lication (I) was the protocol for the COMACARE trial including a detailed plan 
for data collection, statistical analyses, and de nition of the primary and secondary 
outcomes. The main results of the COMACARE trial regarding the pre-de ned pri-
mary and secondary outcomes were reported in studies II and III. Study IV was a 
post hoc analysis of the COMACARE trial assessing the associations between cere-
bral oxygenation, NSE, and neurological outcome. Study V was a pooled analysis 
of the COMACARE and the Neuroprotect 146 trials analysing the e ect of MAP on 
developing myocardial damage after OHCA and AMI.
Table 4  Study characteristics
Study # Study design N:o of 
patients
Main objectives
 I Protocol for a 
randomised trial
N/A To define the methods and outcomes for a randomised 
clinical trial (studies II-III)
 II Prospective 
randomised trial
120 To determine the feasibility of targeting low-normal or high-
normal MAP after OHCA and its effect on markers of 
neurological injury 
 III Prospective 
randomised trial
120 To determine the feasibility of targeting low-normal or high-
normal PaCO2 and normoxia or moderate hyperoxia after 
OHCA and their effect on markers of neurological injury
 IV Post hoc analysis 
of a randomised 
trial
118 To investigate the association of cerebral oxygenation 
during early intensive care with markers of neurological 
injury and neurological outcome after OHCA 
 V Post hoc analysis 
of two randomised 
trials
120 To investigate the association of MAP with the extent of 
myocardial injury in patients with AMI and vasopressor 
dependent hypotension after OHCA
Abbreviations: MAP, mean arterial pressure; OHCA, out-of-hospital cardiac arrest; PaCO2, arterial carbon 
dioxide tension; and AMI, acute myocardial infarction.
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Participants and consent
The eligible participants in the COMACARE trial included adult patients resusci-
tated from witnessed OHCA with a shockable initial rhythm (VF or pulseless VT). 
In addition, all of the inclusion criteria and none of the exclusion criteria had to be 
met (Table 5). Six ICUs in Finland and one in Denmark participated in the trial. All 
patients who were resuscitated from OHCA and admitted to one of the participating 
ICUs were screened for eligibility by a study nurse or ICU sta .
Because of the nature of the trial, the patients’ unconscious state, and the need 
for a timely intervention, obtaining prior informed consent from the participants at 
the time of randomisation was impossible. Therefore, the patients were randomised, 
and the intervention was initiated at the time of ICU admission. Deferred informed 
consent from the patients’ next of kin was obtained as soon as they were present 
at the hospital. After the intervention period, informed consent was also obtained 
from all patients who regained su cient neurological function for independent 
decision making (CPC 1–2).
The study protocol and the deferred consent option were approved by the re-
search ethics committees of the Northern Savo Hospital District, Finland (decision No. 
295/2015) and the Midtjylland region, Denmark (decision No. 1-10-72-163-16). In 
addition, the trial protocol was approved by the institutional review board at each site.
Table 5  Inclusion and exclusion criteria of the COMACARE trial (studies II-III)
Inclusion criteria Exclusion criteria
Witnessed OHCA with VF or pulseless VT as initial 
rhythm 
ROSC 10-45 min 
Confirmed or suspected cardiac origin of the arrest 
Markedly impaired level of consciousness on arrival 
to ICU (GCS motor score < 5) 
Mechanical ventilation 
Deferred consent from next of kin possible or likely 
Active ICU care and TTM initiated
In-hospital cardiac arrest 
Initial rhythm PEA or asystole 
Cardiac arrest with confirmed or suspected non-
cardiac etiology 
Probable withdrawal from active ICU care due to 
terminal illness or poor prognosis because of 
severely reduced functional status before cardiac 
arrest 
Deferred consent impossible or unlikely (no known 
next of kin or relatives) 
Conscious patient or only mild impairment of 
consciousness on arrival to ICU (GCS motor score ≥ 
5) 
Confirmed or suspected acute or pre-existing 
intracranial pathology and/or increased ICP 
Age < 18 or > 80 years 
Pregnancy 
Severe oxygenation failure defined as PaO2/FiO2 < 
100 mmHg upon ICU arrival and no improvement 
after optimization of mechanical ventilation 
Severe COPD
Abbreviations: OHCA, out-of-hospital cardiac arrest; VF, ventricular fibrillation; VT, ventricular tachycardia; 
PEA, pulseless electrical activity; ROSC, return of spontaneous circulation; ICP, intracranial pressure; ICU, 
intensive care unit; GCS, Glasgow Coma Scale; TTM, targeted temperature management; PaO2, arterial 
oxygen tension; FiO2, fraction of inspired oxygen; and COPD, chronic obstructive pulmonary disease.
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Randomisation and blinding
All patients were randomised at the time of ICU arrival by a web-based randomisation 
system (Absolute Imaginary Software, Finland). A cryptographically strong random 
number generator with modulo bias eliminated was used to generate random num-
bers, and an unbiased Fisher-Yates (Durstenfeld) algorithm was used to shu e the 
blocks. The randomisation was strati ed based on the target temperature (33°C or 
36°C). The participants were enrolled and assigned to study interventions by a study 
nurse or the treating clinician in the ICU. Because of the nature of the interventions, 
the treating personnel could not be blinded regarding the treatment targets, moni-
tored vital parameters, the results of the ABG analyses, or daily obtained blood test 
results. However, as NIRS monitoring was not part of the routine post-resuscitation 
care at the study centres, the frontal rSO2 results were not visible to the treating 
personnel. Moreover, the neurophysiologist analysing the EEG results and the neu-
rologist evaluating the neurologic recovery of the participants were blinded to the 
study group allocations.
Interventions
The intervention targets are represented in Table 6. After ICU admission and ran-
domisation, the ICU personnel was guided to target low-normal or high-normal 
PaCO2, normal or moderately elevated PaO2 and low-normal or high-normal MAP 
for 36 h from ICU admission or until the patient was extubated or ventilation was 
set to a spontaneous mode. The designated PaCO2 level was targeted by adjusting 
the tidal volume and ventilation rate delivered by the ventilator. Normoxia or mod-
erate hyperoxia were targeted by adjusting FiO2 and PEEP levels on the ventilator. 
Table 6  Intervention targets in the COMACARE trial (studies II-III)
Group PaCO2 PaO2 MAP
1 4.5-4.7 kPa 10-15 kPa 65-75 mmHg
2 5.8-6.0 kPa 10-15 kPa 65-75 mmHg
3 4.5-4.7 kPa 20-25 kPa 65-75 mmHg
4 5.8-6.0 kPa 20-25 kPa 65-75 mmHg
5 4.5-4.7 kPa 10-15 kPa 80-100 mmHg
6 5.8-6.0 kPa 10-15 kPa 80-100 mmHg
7 4.5-4.7 kPa 20-25 kPa 80-100 mmHg
8 5.8-6.0 kPa 20-25 kPa 80-100 mmHg
Abbreviations: PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension; and MAP, mean 
arterial pressure.
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The ventilator adjustments were guided by ABG analyses performed at least every 3 
hours. The results of the ABG analyses were corrected to each patient’s actual tem-
perature measured from inferior vena cava or the urinary bladder. End-tidal carbon 
dioxide (EtCO2) monitoring was used as an additional guide in targeting the desired 
PaCO2 level. In the normoxia group, peripheral oxygen saturation (SpO2) was used 
as an additional guide, targeting an SpO2 value of 95–98%. A volume-controlled or 
a pressure-controlled ventilation mode was used according to the treating clinician’s 
preference. 
The designated MAP level was targeted by using a continuous infusion of nor-
adrenaline as needed. Hypovolemia was treated with uid boluses according to the 
treating clinicians’ preference. If low CO was con rmed or suspected, the use of an 
inotrope such as dobutamine or levosimendan was allowed. There were no pre-de-
ned limits regarding the infusion rates of noradrenaline or inotropes. In order to 
meet the low-normal MAP target, the blood pressure was not lowered by any means 
other than sedation and/or pain medication. If MAP exceeded 140 mmHg or left 
ventricular systolic dysfunction was detected, the use of vasodilating agents to lower 
the blood pressure according to the treating clinicians’ decision was allowed. All 
patients were treated with TTM at 33 °C or 36 °C according to the local ICU protocol 
and sedated as needed. Standard monitoring, care and investigations according to 
the local ICU protocol were used for all patients.
Except for moderate hyperoxia, all targeted PaCO2, PaO2, and MAP levels were 
within the recommendations of current guidelines 15,147. Regarding PaCO2, target-
ing such a narrow area on the lower or upper end of the normal range could increase 
the risk of intermittent hypocapnia or hypercapnia. However, with frequent ABG 
analyses taken at least every 3 hours and continuous EtCO2 monitoring, the risk was 
not considered to be greater than in the patients receiving standard post-resusci-
tation care. Although the higher PaO2 target was clearly outside the normal range, 
previous studies have not demonstrated harm from this level of hyperoxia, and there 
is some evidence suggesting that it could be bene cial instead 33,57. Thus, both the 
researchers of the study and the ethical committee considered this intervention 
to be ethically justi ed. Regarding MAP, even a small deviation of blood pressure 
below the lower target of 65-75 mmHg would expose the patient to hypotension. 
However, with continuous direct arterial pressure monitoring and a dedicated nurse 
at the patients’ side at all times, the risk was considered to be small and no di erent 
from patients treated with standard post-resuscitation care.  
Outcomes
The primary outcome of the COMACARE trial was the NSE serum concentration 
at 48 h after CA. The main feasibility outcomes were the di erences in PaCO2, PaO2 
and MAP between the intervention groups. The pre-speci ed secondary outcomes 
were serum NSE concentrations at 24 h and 72 h after CA; serum S100B protein 
concentrations at 24 h, 48 h, and 72 h after CA; plasma cardiac troponin (TnT) 
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concentrations at 24 h, 48 h, and 72 h after CA; cerebral oxygenation (frontal rSO2) 
measured by continuous NIRS monitoring during the rst 48 h after admission to 
the ICU; results of continuous EEG monitoring for the rst 48 h after admission to 
the ICU, interpreted by an experienced senior neurophysiologist blinded to the study 
group allocation; neurological outcome determined with the CPC scale at 6 months 
after CA (CPC 1–2 considered as good outcome and CPC 3-5 as poor outcome), 
determined by an experienced neurologist blinded to the study group allocation; 
total duration of intensive care; total duration of mechanical ventilation; length of 
hospital stay; discharge destination; and vital status at 30 days after CA (dead or 
alive). Other feasibility outcomes included distribution of values for primary and 
secondary outcomes, randomised/screened patient ratio, consent rate, data comple-
tion rate and duration of recruitment. The pre-de ned serious adverse events (SAE) 
that could be related to the interventions were severe hypercapnia and respiratory 
acidosis (PaCO2 > 10 kPa and pH < 7.15), unexplained brain oedema on CT scan-
ning, and severe unexplained ARDS (PaO2/FiO2 ratio of < 100 mmHg).
Data collection
Baseline data regarding the participants’ age, gender, prior health status, and func-
tional capacity, as well as details regarding the CA and resuscitation, were entered 
and saved in an electronic study database (Absolute Imaginary Software, Finland). 
SpO2, heart rate, EtCO2 and direct blood pressure measurements (systolic, diastolic 
and mean arterial pressures) via arterial cannula were done every 10 minutes and 
saved in a medically approved tablet computer (Arbor M1040, Taiwan; and S/5 col-
lect software version 4.0, GE Healthcare, USA) connected to the patient monitor 
during the rst 48 h after ICU admission. In case of technical di culties, the values 
of these parameters were obtained later from the ICU software database (PICIS 
Clinical Solutions, USA). The ventilator settings were exported directly from the 
ventilators and saved in a USB drive after the intervention. In case this was not 
possible due to technical problems, the ventilator values were entered manually into 
the electronic database. 
The blood samples for the ABG analyses were obtained via arterial cannula 
and analysed on-site as part of routine ICU care. The results of the ABG analyses, 
corrected to the patient’s actual temperature, were entered manually into the elec-
tronic study database. The doses of sedative and vasoactive drug infusions were also 
entered manually into the database.
The blood samples for the analyses of NSE, S100B and TnT concentrations were 
obtained via arterial cannula upon ICU admission and 24 h, 48 h and 72 h after CA. 
In the Finnish centres, the samples were centrifuged (2000 G, 10 min) and frozen at 
performed using a COBAS e601 line (Hitachi High Technology Co, Japan) with an 
electro chemiluminescent immunoassay kit (Roche Diagnostics GmbH, Germany) 
in January 2018. At the Aarhus University Hospital, Denmark, the samples were 
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analysed immediately by the local laboratory using the same kits as those used by the 
ISLAB laboratory. Because haemolysis can alter the NSE results, all serum samples 
obtained in the Finnish centres were tested for haemolysis using the Roche haemo-
lysis index. All samples with signi cant haemolysis (n = 7), de ned as more than 500 
mg of free Hb per litre, were excluded from the NSE analyses. In the samples taken 
at the Danish centre (n = 26), the NSE concentration was analysed immediately and 
haemolysis was not assessed.
Frontal rSO2 was measured with continuous NIRS during the rst 36-48 h of 
intensive care using a Covidien INVOS 5100C device (Covidien Company, USA). 
Two non-invasive skin sensors, one to each side, were attached to the patient’s fore-
head by a study nurse according to the instructions of the manufacturer. Because 
NIRS monitoring was not part of routine care in the participating ICUs, the treating 
personnel were blinded from its results, and  the rSO2 measurements did not a ect 
patient care. The rSO2 values, approximately 10 measurements per minute from 
both sensors, were saved to a USB memory stick attached to the NIRS device.
Continuous four-channel EEG was recorded with a GE Carescape module (GE 
Healthcare, USA) connected to the patient monitor during the rst 48 h of ICU 
care or until consciousness was regained. The EEG recordings were saved to the 
tablet computer using the S/5 collect software version 4.0 (GE Healthcare, USA). 
One senior neurophysiologist blinded to the study group allocations analysed all the 
EEG recordings after the patient recruitment was completed and categorised them 
into three groups according to the degree of abnormality (mild, moderate or severe, 
as proposed by Crepeau et al 148 at the beginning and at the end of the intervention. 
An experienced senior neurologist blinded to the study group allocations contacted 
all hospital survivors or their surrogates by telephone at six months after CA and 
determined their functional statuses using the CPC scale.
Statistical methods
Categorical data between the intervention groups were compared with a chi-
square test for association. The normality of the continuous data was tested with a 
Kolmogorov-Smirnov test and the data with a normal distribution were compared 
with an independent-samples t-test and the data with a non-normal distribution 
were compared with a Mann–Whitney U test.
Regarding PaCO2 and PaO2, the intervention time was divided into 3 h periods 
starting at the time of ICU admission and the mean PaCO2 and PaO2 was calcu-
lated for each period for each patient. The median of these 3 h means was then 
compared between the low-normal and high-normal PaCO2 groups and normoxia 
and moderate hyperoxia groups over time using a generalized mixed model with 
a compound-symmetry covariance matrix. Regarding MAP, the intervention time 
was divided into 1 h periods starting at the time of ICU admission and the median 
MAP was calculated for each period for each patient. These 1 h medians were then 
compared between the low-normal and high-normal MAP groups over time using a 
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generalized mixed model with a compound-symmetry covariance matrix.
The NSE serum concentrations at 48 h in the di erent intervention groups were 
compared using a Mann–Whitney U test. The NSE, S100B and TnT concentra-
tions and frontal rSO2 values over time were compared using a generalized mixed 
model with a compound-symmetry covariance matrix. The distributions of EEG 
abnormalities (mild, moderate, or severe), 30-day mortality and the six-month CPC 
results between the groups were compared with a Chi-square test for association.
The interaction e ect of the PaCO2, PaO2 and MAP targets with the TTM, 
PaCO2, PaO2 and MAP targets on the NSE results at 48 h was analysed with univar-
iate analysis of variance. The interaction e ect of the PaCO2, PaO2 and MAP targets 
with the TTM, PaCO2, PaO2 and MAP targets on the CPC results at 6 months was 
analysed with a binary logistic regression model.
All statistical analyses were done with the SPSS Statistics version 24.0 (IBM 
Corporation, USA).
Neuroprotect trial
The Neuroprotect trial was a randomised clinical trial aiming to investigate whether 
an early goal-directed haemodynamic optimisation during the rst 36 of post-re-
suscitation care would reduce HIE and improve outcomes when compared with 
standard care. A total of 112 OHCA patients in two hospitals in Belgium were ran-
domly assigned to targeting either MAP 65 mmHg or MAP 85-100 mmHg during 
the rst 36 h after ICU admission 146. In the higher MAP group, there was an addi-
tional target of SvO2 65-75%. All adult patients who were resuscitated from OHCA 
with a presumed cardiac cause and who remained unconscious (GCS < 8) at hospital 
admission were screened for eligibility. The exclusion criteria were suspected or 
con rmed intracranial bleeding or stroke, known limitations in therapy or a Do Not 
Resuscitate -order, known disease compromising 180 day survival, CPC 3-4 before 
CA, previous stroke or TIA, MRI incompatible cardiac or neurosurgical device, sys-
tolic blood pressure < 90 mmHg on norepinephrine > 1 g/kg/min, open chest, 
extracorporeal membrane oxygenation (ECMO) initiated, or pregnancy. Written 
informed consent was obtained from a next of kin, or if unavailable, a procedure 
for inclusion in emergency situations was applied. A de nitive post-hoc consent 
form was ultimately obtained from all patients who recovered su ciently to make 
independent decisions. SvO2 65-75% was targeted with optimising uid status, 
maintaining the Hb level over 100 g/l, treating excessive bradycardia (HR < 40/min) 
and infusing dobutamine as necessary starting with 5 g/kg/min. The designated 
MAP level was targeted with a continuous infusion of noradrenaline as needed. All 
patients were treated with standard post-CA care including intubation, mechanical 
ventilation, sedation, and TTM at 33 °C.
The primary outcome of the Neuroprotect trial was the extent of anoxic brain 
injury, measured with the percentage of ischaemic voxels with an apparent di u-
sion coe cient below 650.10-6 mm2/s on di usion weighted magnetic resonance 
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imaging (MRI) performed 4-6 days after CA. The secondary outcomes were favour-
able neurological outcome at ICU discharge and at 180 days de ned as CPC 1-2, 
length of ICU stay, duration of mechanical ventilation, need for tracheostomy, NSE 
concentrations during days 1-5, creatinine concentrations and diuresis during days 
1-5, 6 minute walking distance at hospital discharge, and all-cause mortality at 180 
days.
Post hoc analyses
Association of cerebral oxygenation with NSE and neurological 
outcome
The rst post hoc analysis (IV) investigated the association of frontal rSO2 during 
the rst 36 h of ICU care after OHCA with NSE concentrations at 24 h, 48 h, and 
72 after CA; and the association of rSO2 with dichotomised neurological outcome 
(CPC 1-2 considered as good outcome and CPC 3-5 as poor outcome) at six months. 
In addition, the association of NSE concentration with good and poor neurological 
outcome was assessed. The methods of the data collection for frontal rSO2, NSE con-
centrations and neurological outcome have been described above. The median NSE 
concentrations at 48 h after CA between patients with good and poor neurological 
outcome at 6 months were compared using a Mann–Whitney U test. The median 
frontal rSO2 during the rst 36 h of intensive care was calculated for each patient 
and the association between median rSO2 and NSE concentrations at 24, 48 and 
72 h was assessed using a scatterplot and a Spearman’s rank-order correlation. The 
36-h median rSO2 between patients with good and those with poor outcome were 
compared using a Mann–Whitney U test. The rSO2 over time between patients with 
good and those with poor outcome was compared using a generalized mixed model 
with a compound symmetry covariance matrix. A binary logistic regression model 
was used to ascertain the e ects of baseline factors and rSO2 on the likelihood of good 
neurological outcome. The factors that were signi cantly associated with prognosis 
(p < 0.05) in univariate analysis were selected. These factors were age, bystand-
er-initiated resuscitation, delay from collapse to ROSC, and Acute Physiology and 
Chronic Health Evaluation (APACHE) II score. In addition, the cohort was divided 
into tertiles according to the lowest 60-min median rSO2 during the 36-h period, 
and the probability for a good outcome with 95% con dence interval was calculated 
for each tertile. The area under the receiver operating characteristic curve with 95% 
con dence interval was calculated for the lowest 60-min median rSO2 to predict 
good outcome in each tertile.
Arterial pressure and myocardial damage in AMI patients
The second post hoc analysis (V) was a pooled analysis of two trials: the COMACARE 
trial and the Neuroprotect trial, a randomised clinical trial investigating the e ect of 
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early goal-directed haemodynamic optimisation on brain injury in patients resusci-
tated after OHCA 146. The aim was to investigate the possible association between 
MAP level and the extent of myocardial injury in a subgroup of patients with AMI 
and vasopressor dependent hypotension.
All COMACARE and Neuroprotect patients with AMI and vasopressor depen-
dent hypotension were included in the pooled analysis. Because chest pain could not 
be assessed and practically all CA patients have some form of ECG abnormalities and 
elevated cardiac troponin levels, the universal criteria for AMI could not be used. 
Instead, AMI was de ned as either ST-elevations in the ECG (STEMI) or as a non-
STEMI with identi cation of a clear culprit lesion (a coronary lesion with at least 
70% stenosis and the presence of characteristics of plaque disruption) in coronary 
angiography performed within 2 hours after hospital admission. The primary end-
point was myocardial infarct size assessed by the area under the 72-hour TnT curve. 
TnT was measured at hospital admission and at 24, 48 and 72 hours after CA in both 
trials. In the Neuroprotect trial, there was an additional troponin measurement at 5 
hours. Additional TnT measurements were made during the rst 72 h according to 
local protocol and orders by the treating clinician, and all these results were included 
in the nal analyses. The determination of the TnT concentration was performed 
using a COBAS e601 line (Hitachi High Technology Co, Tokyo, Japan) with an elec-
tro chemiluminescent immunoassay kit (Roche Diagnostics GmbH, Mannheim, 
Germany).
The area under the 72-hour TnT curve was compared between both groups 
using a Van Elteren test that included the study (Neuroprotect/COMACARE) as 
a strati cation factor. For missing TnT data of patients who died before 72 h, the 
missing value was replaced with the highest TnT in the corresponding treatment 
group. Missing data from patients surviving beyond 72 h were imputed by regres-
sion analysis on the logarithmically transformed TnT values. In cases where the 
TnT measurement was missing at the time of ICU admission, the value was imputed 
with the median value observed in the study at ICU admission. Longitudinal data 
(MAP, diastolic blood pressure, heart rate, dose norepinephrine and dobutamine) 
were analysed using a generalized estimating equation model for normally distrib-
uted data that included factors for time (included as a categorical variable), treatment, 
study and their interactions. The model included an exchangeable working correla-
tion matrix to account for within-patient correlations. Di erences in the pro les 
over time between the two treatment groups were assessed by the interaction. SPSS 
Statistics version 24.0 (IBM Corporation, USA), SAS version 9.4 (SAS Institute Inc, 





The rst patient of the COMACARE trial was randomised on 22 March 2016 and 
the recruitment was completed by 3 November 2017. The 6-month follow-up of 
the last patient was completed by 3 May 2018. The owchart demonstrating patient 
enrolment and group allocation is presented in Figure 1. The baseline characteristics 
and resuscitation-associated factors were comparable between the groups (Table 7). 
Overall, 78 of 120 patients (65%) had good neurological outcome (CPC 1-2) at six 
months. Three patients had severe cerebral disability (CPC 3) and there were no 
patients in coma or vegetative state (CPC 4). At the end of the 6-month follow-up, 
39 (33%) patients had died. In 34 of the dead patients (87%) the cause of death was 
HIE. All of the dead patients except one died before 30 days after CA. 
Feasibility outcomes
A clear separation in PaCO2, PaO2 and MAP was observed between the groups 
during the intervention (Figures 2-4). Minute ventilation was higher in the low-nor-
mal PaCO2 group than in the high-normal PaCO2 group. The median (interquartile 
range [IQR]) expiratory tidal volume per body weight and the median (IQR) venti-
lation rate were 5.8 (5.2–6.8) ml/kg and 12 (12–14) min  vs. 5.4 (4.8–5.9) ml/kg and 
11 (10–12) min , respectively. The median (IQR) FiO2 and PEEP levels were 35% 
(30–40%) and 7.2 (6.2–8.2) cmH2O in the normoxia group and 50% (45–59%) and 8.2 
(6.3–10.0) cmH2O in the moderate hyperoxia group, respectively. The median (IQR) 
noradrenaline dose used was 0.05 (0.02–0.11) g/kg/min in the low-normal MAP 
group and 0.13 (0.08–0.20) g/kg/min in the high-normal MAP group. 
Primary outcome
There were no signi cant di erences in serum NSE concentrations at 48 h after 
CA between the intervention groups (Table 8). The median (IQR) serum NSE con-
centration at 48 h after CA was 18.8 (13.9–28.3) g/l in the low-normal PaCO2 
group and 22.5 (14.2– 34.9) g/l in the high-normal PaCO2 group, p = 0.400; 22.3 
(14.8–27.8) g/l in the normoxia group and 20.6 (14.2–34.9) g/l in the moderate 
hyperoxia group, p = 0.594; and 20.6 (15.2–34.9) g/l in the low-normal MAP group 
and 22.0 (13.6– 30.9) g/l in the high-normal MAP group, p = 0.522.
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14 
assigned to  
group 1
15 
assigned to  
group 2
16 
assigned to  
group 3
15 
assigned to  
group 4
17 
assigned to  
group 5
15 
assigned to  
group 6
14 
assigned to  
group 7
14 
assigned to  
group 8
229 Excluded
185 Did not meet inclusion criteria a
71 Met exclusion criteria b
17 Excluded because there was no 
study personnel available
7 Excluded because study 
equipment was not functional or 
available 
9 Excluded for other reasons c
352  Patients admitted to ICU after OHCA and 
assessed for eligibility
123  Randomised
60  Assigned to low-normal MAP 
for 36 h
3  Excluded after randomisation d
61  Assigned to normoxia for 
36 h
60  Assigned to high-normal MAP 
for 36 h
59  Assigned to moderate 
hyperoxia for 36 h
61  Assigned to low-normal PaCO2 
for 36 h
59  Assigned to high-normal 
PaCO2 for 36 h
120  Assigned to intervention groups and included 
in the final analysis
Figure 1  Screened, excluded and included patients in studies II-III and the 
allocations to different intervention groups
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No signi cant di erences in the NSE, S100B or TnT concentrations over time were 
found between the low-normal and high-normal PaCO2 groups, the normoxia 
and moderate hyperoxia groups or the low-normal and high-normal MAP groups 
(Figures 5-7). The frontal rSO2 was signi cantly higher in the high-normal PaCO2 
and moderate hyperoxia groups than in the low-normal PaCO2 and normoxia 
groups, respectively, p < 0.001 (Figures 8-9). In the low-normal and high-normal 
MAP groups the frontal rSO2 values were comparable over time (Figure 10). The 
EEG grading at ICU admission and at the end of the intervention was comparable in 
all groups (Table 9). There were no signi cant di erences between any of the groups 
regarding mortality at 30 days after CA, good neurological recovery (CPC 1–2) at 6 
months after CA, the duration of intensive care or mechanical ventilation, or the 
frequency of the prede ned SAEs (Table 8).
Association of cerebral oxygenation with NSE and 
neurological outcome
A total of 118 patients with continuous NIRS monitoring during the rst 36 h of 
post-resuscitation intensive care were included in the analysis. Of these, 78 patients 
(66%) had CPC 1-2 and 40 patients (34%) CPC 3-5 at six months after CA (Figure 
11). In univariate analysis, patient age, history of chronic heart failure, cardiac arrest 
location, bystander-initiated resuscitation, delay from collapse to ROSC, APACHE 
II score, and target temperature were signi cantly associated with the dichoto-
mised neurological outcome at six months (Table 10). Median (IQR) serum NSE 
concentration at 48 h was 17.5 (13.4–25.0) g/l in patients with good neurological 
outcome and 35.2 (22.6–95.8) g/l in patients with poor neurological outcome, p < 
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Number of patients 61 59
Demographic characteristics
Age, mean ± SD, years 58 ± 11 61 ± 15
Male sex, n (%) 53 (87) 45 (76)
Weight, mean ± SD, kg 86 ± 17 83 ± 16
Neurologic function before cardiac arrest
Normal, CPC score 1, n (%) 56 (92) 55 (93)
Some disability, CPC score 2, n (%) 5 (8) 4 (7)
Medical history
Antihypertensive medication, n (%) 27  (44) 33 (56)
Chronic heart failure (NYHA class IV), n (%) a 2 (3) 0
Inhaled corticosteroids, n (%) 1 (2) 5 (8)
Inhaled bronchodilators, n (%) 2 (3) 6 (10)
Smoker, n (%) b 25 (41) 15 (25)
Cardiac arrest location
Home, n (%) 34 (56) 26 (44)
Public place, n (%) 27 (44) 33 (56)
Resuscitation factors
Bystander-initiated resuscitation, n (%) 50 (82) 48 (81)
Time to BLS, median (IQR), min 7 (5-9) 8 (6-10)
Time to ALS, median (IQR), min 9 (7-12) 10 (8-13)
Time to ROSC, median (IQR), min 20 (16-25) 21 (17-26)
Intubated during resuscitation, n (%) 30 (49) 27 (46)
Immediate interventional cardiology
Pre-hospital thrombolysis, n (%) 2 (3) 2 (3)
Coronary angiography before ICU admission, 
n (%)
31 (51) 32 (54)
Clinical status on ICU admission
GCS after ROSC, median (IQR) c 3 (3-3) 3 (3-3)
APACHE II score, median (IQR) 27 (24-30) 29 (25-33)
Pre-hospital cooling, n (%) 5 (8) 5 (8)
Dose of norepinephrine, mean ± SD, g/kg/min 0.07 ± 0.1 0.07 ± 0.1
Time from ROSC to randomization, median (IQR), 
min
159 (130-204) 180 (143-216)
Targeted temperature management
33 ºC, n (%) 43 (70) 40 (68)











61 59 60 60
59 ± 13 60 ± 14 61 ± 11 58 ± 14
50 (82) 48 (81) 48 (80) 50 (83)
83 ± 15 86 ± 18 86 ± 19 83 ± 14
56 (92) 55 (93) 57 (95) 54 (90)
5 (8) 4 (7) 3 (5) 6 (10)
31 (51) 29 (49) 26 (43) 34 (57)
2 (3) 0 (0) 0 2 (3)
5 (8) 1 (2) 4 (7) 2 (3)
5 (8) 3 (5) 5 (8) 3 (5)
19 (31) 21 (36) 20 (33) 20 (33)
33 (54) 27 (46) 32 (53) 28 (47)
28 (46) 32 (54) 28 (47) 32 (53)
50 (82) 48 (81) 51 (85) 47 (78)
7 (6-10) 7 (6-9) 8 (6-10) 7 (5-9)
10 (8-12) 10 (7-12) 10 (7-12) 10 (7-12)
20 (16-25) 21 (16-27) 22 (16-27) 19 (15-25)
28 (46) 29 (49) 26 (43) 31 (52)
2 (3) 2 (3) 3 (5) 1 (2)
35 (57) 28 (47) 35 (58) 28 (47)
3 (3-3) 3 (3-3) 3 (3-3) 3 (3-3)
27 (24-31) 28 (25-31) 28 (24-32) 27 (24-31)
3 (5) 7 (12) 4 (7) 6 (10)
0.07 ± 0,1 0.07 ± 0,1 0.06 ± 0.08 0.08 ± 0.11
178 (139-216) 166 (135-192) 171 (148-214) 172 (128-204)
41 (67) 42 (71) 42 (70) 41 (68)
20 (33) 17 (29) 18 (30) 19 (32)
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Table 7  Continued
Abbreviations: PaCO2, arterial carbon dioxide tension; SD, standard deviation; IQR, inter-
quartile range; CPC, Cerebral Performance Category [1, good cerebral performance (normal 
life); 2, moderate cerebral disability (disabled but independent); 3, severe cerebral disability 
(conscious but disabled and dependent); 4, coma or vegetative state (unconscious); 5, brain 
death]; NYHA, New York Heart Association; BLS, basic life support; ALS, advanced life 
support; ROSC, return of spontaneous circulation; ICU, intensive care unit; GCS, Glasgow 
coma scale; and APACHE, acute physiology and chronic health evaluation. 
 a Data missing for 2 patients, b data missing for 13 patients, c data missing for 9 patients
Figure 2  Median (inter-quartile range) arterial carbon dioxide tension (PaCO2) 
during the intervention in patients assigned for targeting low-normal and high-
normal PaCO2 in study III



















High-normal PaCO2 Low-normal PaCO2
0.001. Serum NSE concentration over time was signi cantly higher in patients with 
poor neurological outcome, p < 0.001 (Figure 12). No statistically signi cant asso-
ciation was observed between median frontal rSO2 during the rst 36 h in the ICU 
p = 0.392 (Figure 13). 
Moreover, there was no association between median frontal rSO2 during the rst 36 
h in the ICU and serum NSE concentrations at 24 h or 72 h after CA. 
The median (IQR) frontal rSO2 during the rst 36 h of ICU care was 70.0% 
(63.5–77.0%) in patients with good neurological outcome and 71.8% (63.3–74.0%) 
in patients with poor neurological outcome, p = 0.943. There was no signi cant 
association between frontal rSO2 over time and neurological outcome (Figure 14). 
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Figure 3  Median (inter-quartile range) arterial oxygen tension (PaO2) during the 
intervention in patients assigned for targeting normoxia and moderate hyperoxia in 
study III

















Figure 4  Median (inter-quartile range) mean arterial pressure (MAP) during the 
intervention in patients assigned for targeting low-normal and high-normal MAP in 
study II
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In the binary logistic regression model, the median frontal rSO2 during the rst 36 
h in the ICU was not a statistically signi cant predictor of good outcome (adjusted 
odds ratio [OR] 0.99, 95% con dence interval 0.94–1.04, p = 0.635). In addition, the 
worst 60-min median frontal rSO2 did not associate with good neurological out-
come (Table 11).
Arterial pressure and myocardial damage in 
resuscitated patients with AMI
In total, 235 patients were randomised in the COMACARE (n = 123) and Neuro-
protect (n = 112) trials. Of these, 93 patients did not have AMI and 17 patients did 
not undergo an immediate angiography, and they were excluded from the pooled 
analysis. In addition, the next of kin of four patients refused informed consent and 
there was one randomisation error. Thus, the pooled analysis consisted of 120 AMI 
patients of whom 58 were randomised to the MAP 80/85-100 mmHg group and 62 
to the MAP 65 mmHg group (Figure 15). The pre-randomisation characteristics 
were comparable in both groups (Table 12). The majority of patients had ST seg-
ment elevation on the ECG upon hospital admission (79% in the higher MAP group 
vs. 85% in the lower MAP group, p = 0.37). All 120 patients underwent immedi-
ate angiography with an attempt for percutaneous intervention (PCI) of the culprit 
artery. The mean ± standard deviation (SD) time from ROSC to coronary angiogra-
phy was comparable in both groups (73 ± 50 min in the higher MAP group vs. 66 ± 
48 min in the lower MAP group, p = 0.85).
All 120 patients needed vasopressor support in order to achieve and maintain 
the designated MAP target. Patients assigned to the higher MAP group received sig-
ni cantly higher doses of norepinephrine as compared with the lower MAP group 
(median [IQR] 0.17 [0.08-0.30] g/kg/min vs 0.08 [0.01-0.15] g/kg/min, p = 
0.004) and their MAP level was consistently higher during the intervention (Figure 
16). The number of patients receiving dobutamine was comparable in both groups 
(14/58 (24%) vs 11/62 (18%), p = 0.39), but the mean ± SD dobutamine dose was 
signi cantly higher in patients assigned to the higher MAP group (4.5 ± 4.2 g/kg/
min vs. 3.7 ± 2.2 g/kg/min, p = 0.01).
Myocardial damage, as quanti ed as the area under the 72-hour cardiac TnT 
curve, was greater in the lower MAP group than in the higher MAP group (median 
[IQR] 112 [44-340] gh/l vs. 82 [25-166] gh/l, p = 0.04, respectively) (Figure 17 
and Table 13). The additional inotropic and vasopressor support in the higher MAP 
group did not increase the risk of a new onset CA (8/58 [14%] in the higher MAP 
group vs. 9/61 [15%] in the lower MAP group, OR 0.92 [95% CI 0.33-2.58], p = 0.88) 
or new onset atrial brillation (4/58 [7%] in the higher MAP group vs. 4/61 [7%] in 
the lower MAP group, OR 1.05 [95% CI 0.25-4.43], p = 0.94) (Table 13).
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Figure 5  Baseline, 24 h, 48 h, and 72 h median (inter-quartile range) (a) serum 
neuron-specific enolase (NSE) concentrations, (b) serum S100B protein 
concentrations, and (c) plasma cardiac troponin (TnT) concentrations in patients 
assigned for targeting low-normal and high-normal arterial carbon dioxide tension 
(PaCO2) in study III
































































Figure 6  Baseline, 24 h, 48 h, and 72 h median (inter-quartile range) (a) serum 
neuron-specific enolase (NSE) concentrations, (b) serum S100B protein 
concentrations, and (c) plasma cardiac troponin (TnT) concentrations in patients 


































































Figure 7  Baseline, 24 h, 48 h, and 72 h median (inter-quartile range) (a) serum 
neuron-specific enolase (NSE) concentrations, (b) serum S100B protein 
concentrations, and (c) plasma cardiac troponin (TnT) concentrations in patients 
















































































High-normal PaCO2 Low-normal PaCO2
Figure 8  Median (inter-quartile range) frontal regional oxygen saturation (rSO2) 
during the intervention in patients assigned for targeting low-normal and high-
normal arterial carbon dioxide tension (PaCO2) in study III 
Moderate hyperoxia














Figure 9  Median (inter-quartile range) frontal regional oxygen saturation (rSO2) 
during the intervention in patients assigned for targeting normoxia and moderate 
hyperoxia in study III
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High-normal MAP














Table 9  Number of patients (%) in each EEG grading category in the intervention 


















ICU admission 1 17 (29) 14 (24) 19 (32) 12 (20) 12 (20) 19 (32)
2 3 (5) 2 (3) 1 (2)) 4 (7) 2 (3) 3 (5)
3 39 (66) 43 (73) 39 (66) 43 (73) 45 (75) 37 (62)
p = 0.710 p = 0.167 p = 0.278
End of the 
intervention
1 43 (73) 35 (59) 43 (73) 35 (59) 39 (65) 39 (65)
2 3 (5) 4 (7) 4 (7) 3 (5) 3 (5) 4 (7)
3 13 (22) 20 (34) 12 (20) 21 (36) 17 (28) 16 (27)
p = 0.294 p = 0.181 p = 0.917
Abbreviations: EEG, electroencephalography; PaCO2, arterial carbon dioxide tension and ICU, intensive 
care unit.
1 EEG grading system for continuous EEG findings following cardiac arrest according to Crepeau et al: mild 
(grade 1), moderate (grade 2) and severe (grade 3). 
Figure 10  Median (inter-quartile range) frontal regional oxygen saturation (rSO2) 
during the intervention in patients assigned for targeting low-normal and high-
normal mean arterial pressure (MAP) in study II 
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Figure 11  Screened, excluded and included patients in study IV and neurological 
outcome at six months after cardiac arrest 
a Reasons for exclusion are represented in detail in Figure 1 
Abbreviations: ICU, intensive care unit; OHCA, out-of-hospital cardiac arrest; 
PaCO2, arterial carbon dioxide tension, PaO2, arterial oxygen tension; MAP, mean 
arterial pressure; NIRS, near-infrared spectroscopy and CPC, Cerebral 
Performance Category. 
352  Patients admitted to ICU after OHCA 
and assessed for eligibility
123  Randomised
120  Assigned to one of the 8 combinations of 
PaCO2, PaO2 and MAP for 36 h
3  Excluded after 
randomisation a
118  included in the analysis
2  Excluded because of 
failed NIRS monitoring
229  Excluded a
40  with poor neurological 
outcome (CPC 3-5)
78 with good neurological 
outcome (CPC 1-2)
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Table 10  Baseline characteristics of the study population in study IV according to 
good (CPC 1-2) or poor (CPC 3-5) neurological outcome at six months after 
cardiac arrest
CPC 1-2 CPC 3-5 p value
Number of patients 78 40
Demographic characteristics
Age, mean ± SD, years 58 ± 13 63 ± 13 0.018
Male sex, n (%) 65 (83) 31 (78) 0.441
Weight, mean ± SD, kg 84 ± 16 86 ± 19 0.932
Neurologic function before cardiac arrest 0.582
Normal, CPC score 1, n (%) 72 (92) 38 (95)
Some disability, CPC score 2, n (%) 6 (8) 2 (5)
Medical history
Antihypertensive medication, n (%) 36  (46) 23 (58) 0.243
Chronic heart failure (NYHA class IV), n (%) a 0 (0) 2 (5) 0.046
Inhaled corticosteroids, n (%) 1 (3) 5 (8) 0.360
Inhaled bronchodilators, n (%) 5 (6) 3 (8) 0.824
Smoker, n (%) b 25 (32) 15 (38) 0.161
Cardiac arrest location 0.038
Home, n (%) 33 (42) 25 (63)
Public place, n (%) 45 (58) 15 (38)
Resuscitation factors
Bystander-initiated resuscitation, n (%) 68 (87) 29 (73) 0.048
Time to basic life support, median (IQR), min 7 (6-9) 8 (6-10) 0.672
Time to advanced life support, median (IQR), min 9 (7-11) 11 (7-13) 0.131
Time to ROSC, median (IQR), min 17 (14-22) 25 (21-31) < 0.001
Intubated during resuscitation, n (%) 31 (40) 26 (65) 0.009
Immediate interventional cardiology
Pre-hospital thrombolysis, n (%) 2 (3) 2 (5) 0.489
Coronary angiography before ICU admission, n (%) 37 (48) 24 (60) 0.196
Clinical status on ICU admission
GCS after ROSC, mean ± SD, min c 4 ± 2 3 ± 0 < 0.001
APACHE II score, median (IQR) 27 (24-29) 30 (26-34) 0.014
Pre-hospital cooling, n (%) 9 (12) 1 (3) 0.095
Dose of norepinephrine, mean ± SD, g/kg/min 0.07 ± 0.1 0.06 ± 0.1 0.712
Time from ROSC to randomisation, median (IQR), 
min
173 (134-216) 170 (141-202) 0.874
Targeted temperature management 0.004
33 ºC, n (%) 61 (78) 21 (53)
36 ºC, n (%) 17 (22) 19 (48)
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Table 11  The probability for a good outcome (CPC 1-2) and the area under the 
receiver operating  characteristics curve for the lowest 60-minute median rSO2 to 
predict good outcome overall and in tertiles based on the lowest 60-minute 
median rSO2 during the first 36 h in ICU in study IV
CPC 1-2, % (95% CI) AUC (95% CI)
All patients 66.1 (57.3-74.2) 0.524 (0.416-0.631)
Tertile group according 
to the  lowest 60 min 
median rSO2
1 68.3 (53.2-80.9) 0.544 (0.353-0.735)
2 60.0 (44.6-74.1) 0.520 (0.337-0.702)
3 70.3 (54.4-83.1) 0.594 (0.389-0.800)
Abbreviations: CPC, Cerebral Performance Category; rSO2, regional cerebral oxygen saturation; ICU, 
intensive care unit; CI, confidence interval; AUC, area under the curve.
Table 10  Continued
Abbreviations: CPC, Cerebral Performance Category [1, good cerebral performance (normal life); 2, 
moderate cerebral disability (disabled but independent); 3, severe cerebral disability (conscious but 
disabled and dependent); 4, coma or vegetative state (unconscious); 5, brain death]; SD, standard 
deviation; IQR, inter-quartile range; NYHA, New York Heart Association; CPR, cardiopulmonary 
resuscitation; ICU, intensive care unit; GCS, Glasgow coma scale; ROSC, return of spontaneous circulation; 
and APACHE, acute physiology and chronic health evaluation. 
a Data missing for 2 patients, b data missing for 13 patients, c data missing for 9 patients
Figure 12  Baseline, 24 h, 48 h, and 72 h median (inter-quartile range) serum 
neuron-specific enolase (NSE) concentrations in patients with good (Cerebral 
Performance Category [CPC] 1-2) and poor (CPC 3-5) neurological outcome in 
study IV 


















































Figure 13  Scatter plots of serum neuron-specific enolase (NSE) concentration at 
48 h after cardiac arrest vs. median regional cerebral oxygen saturation (rSO2) 
during the first 36 h in intensive care unit in patients with good (Cerebral 
Performance Category [CPC] 1-2) and poor (CPC 3-5) neurological outcome in 
study IV 
CPC 3-5CPC 1-2
Figure 14  Median (inter-quartile range) regional cerebral oxygen saturation (rSO2) 
during the first 36 h of intensive care in patients with good (Cerebral Performance 
Category [CPC] 1-2) and poor (CPC 3-5) neurological outcome in study IV 
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235  Patients randomised in the COMACARE 
and Neurorpotect trials
119  Assigned to MAP 80/85-100 mmHg116  Assigned to MAP 65 mmHg
61 Excluded
47 Had no AMI b
9 No immediate coronary 
angiography or PCI  




46 Had no AMI a
8 No immediate coronary 
angiography or PCI  
62  Assigned to MAP 65 mmHg 58  Assigned to MAP 80/85-100 mmHg
Figure 15  Screened, excluded and included patients in study V and allocation to 
different MAP arms 
a Reasons for cardiac arrest in patients not meeting AMI criteria were as follows: 
arrhyhtmia (n=37), hypoxia (n=3), intracranial hemorrhage (n=1), pulmonary 
embolism (n=1), cause unclear (n=4). 
b Reasons for cardiac arrest in patients not meeting AMI criteria were as follows: 
arrhyhtmia (n=36), hypoxia (n=8), stroke (n=1), aortic dissection (n=1), cause 
unclear (n=1). 
Abbreviations: MAP, mean arterial pressure; AMI, acute myocardial infarction; and 
PCI, percutaneous coronary intervention.
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Table 12  Baseline characteristics of the study population in study V
COMA 
CARE






Number of patients 61 59 58 62
Demographic characteristics
Age, mean ± SD, years 60 ± 10 65 ± 11 0.31 62 ± 10 63 ± 11 0.48
Male sex, n (%) 54 (88) 50 (85) 0.69 51 (88) 53 (85) 0.69
Medical history
Previous AMI, n (%) 8 (13) 9 (16) 0.68 5 (9) 12 (20) 0.11
Previous arrhytmia, n (%) 6 (10) 5 (9) 0.82 3 (5) 8 (13) 0.15
Arterial hypertension, n (%) 32 (47) 25 (46) 0.89 27 (50) 27 (44) 0.54
Betablocker, n (%) 11 (18) 11 (21) 0.75 10 (19) 12 (20) 0.81
Calcium channel blocker, n (%) 7 (12) 6 (11) 0.95 5 (9) 8 (13) 0.47
ACE-inhibitor / Angiotensin 
receptor blocker, n (%)
17 (28) 11 (21) 0.35 12 (22) 16 (27) 0.54
Diabetes mellitus, n (%) 9 (15) 4 (7) 0.19 8 (14) 5 (8) 0.33
COPD, n (%) 5 (8) 4 (7) 0.79 4 (7) 5 (8) 0.83
Stroke, n (%) 4 (7) 4 (7) 0.94 5 (9) 3 (5) 0.39
Cardiac arrest characteristics
Public place, n (%) 34 (56) 33 (56) 0.98 32 (55) 35 (56) 0.89
Bystander-initiated resuscitation, 
n (%)
50 (82) 40 (69) 0.10 45 (79) 45 (73) 0.42
Initial rhythm <0.01 0.87
Shockable (VF or pulseless 
VT), n (%)
61 (100) 46 (78) 52 (90) 55 (89)
Non-shockable (PEA or 
asystole), n (%)
0 (0) 13 (22) 6 (10) 7 (11)
Time to ROSC, min ± SD 21 ± 8 21 ± 12 0.86 21 ± 10 21 ± 10 0.70
Admission characteristics
Pupillary reflexes present, n (%) 30 (59) 27 (55) 0.70 23 (52) 34 (61) 0.40












SOFA score 8.43 ± 2.28 9.72 ± 2.86 0.19 9.09 ± 2.37 8.98 ± 2.86 0.13
TTM target <0.01 0.89
 33 ºC, n (%) 45 (74) 59 (100) 50 (86) 54 (87)
 36 ºC, n (%) 16 (26) 0 (0) 8 (14) 8 (13)
Abbreviations: MAP, mean arterial pressure; SD, standard deviation; AMI, acute myocardial infarction; ACE, 
angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease; VF, ventricular fibrillation; 
VT, ventricular tachycardia; PEA, pulseless electrical activity; ROSC, return of spontaneous circulation; ICU, 
intensive care unit; SOFA, sequential organ failure assessment; and TTM, targeted temperature 
management.
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Figure 16  (a) Median (inter-quartile range [IQR]) mean arterial pressure (MAP) 
and (b) median (IQR) dose of nordadrenalin in the groups targeting MAP 65 mmHg 
and MAP 80/85-100 mmHg in study V  
a
b
















MAP 65 mmHgMAP 80/85-100 mmHg
p < 0.001

































Figure 17  Median (inter-quartile range) cardiac troponin T (TnT) concentration 
during the first 72 h of intensive care in patients targeting mean arterial pressure 













MAP 65 mmHgMAP 80/85-100 mmHg
p = 0.04






Median (IQR) area under the 72h TnT curve, 
gh/l
82 (25-166) 112 (44-340) 0.04
New onset atrial fibrillation, n (%) 4 (7) 4 (7) 0.94
Recurrent cardiac arrest, n (%) 8 (14) 9 (15) 0.88
CPC 1-2 at 6 months after cardiac arrest, n (%) 37 (64) 33 (53) 0.24
All-cause mortality at 6 months after cardiac 
arrest, n (%)
21 (36) 25 (40) 0.63
Median (IQR) lenght of ICU stay (survivors), 
days
4.91 (3.70-7.00) 6.12 (4.98-10.0) 0.07
Median (IQR) duration of mechanical 
ventilation (survivors), days
2.47 (1.96-4.00) 3.62 (2.83-6.00) 0.07
Abbreviations: MAP, mean arterial pressure; IQR, inter-quartile range; TnT, cardiac troponin T; CPC, Cerebral 




The current study was a randomised pilot trial assessing the feasibility of target-
ing two di erent levels of PaCO2, PaO2, and MAP after OHCA, and comparing the 
e ects of these interventions on biomarkers of brain injury, myocardial injury, brain 
oxygenation and epileptic activity during the post-resuscitation intensive care. We 
found that targeting a speci c level of PaCO2, PaO2 and MAP was feasible in coma-
tose, mechanically ventilated patients, but it did not change the concentration of 
NSE at 48 h after CA or at any other studied time points. Concentrations of S100B 
protein and cardiac TnT and the EEG ndings were also comparable between the 
intervention groups. Targeting high-normal PaCO2 or moderate hyperoxia both 
increased cerebral oxygenation measured by NIRS but the clinical implications of 
this are unclear. In contrast, MAP level did not a ect cerebral oxygenation. No 
signi cant association between cerebral oxygenation measured by NIRS and NSE 
concentrations at 48 h after CA was found, nor between cerebral oxygenation and 
neurological outcome at 6 months. In a subgroup of OHCA patients with AMI and 
vasopressor dependent hypotension, targeting a higher MAP of 80/85-100 mmHg 
was associated with smaller myocardial damage when compared with a MAP target 
of 65 mmHg.
Feasibility of targeting different PaCO2, PaO2, and 
MAP levels
One of the main purposes of this pilot study was to evaluate the feasibility of tar-
geting two di erent levels of PaCO2, PaO2, and MAP in OHCA patients before a 
possible full-scale trial in the future. Although the relationship between MV and 
PaCO2, FiO2 and PaO2, and noradrenaline dose and MAP may seem trivial, very 
little data on the tight control of these parameters in resuscitated patients exist. 
Before a larger randomised trial can be conceived, it is crucial to know whether the 
planned intervention is feasible with real patients in the established clinical setting.
In previous studies, only a weak correlation between prescribed MV and measured 
PaCO2 has been found in CA patients soon after ROSC 37. Moreover, inadvertent 
PaCO2 derangements are common during post-resuscitation care despite the aim for 
normoventilation 98,32,33. However, in a randomised controlled trial comparing mild 
hypercapnia with normocapnia, the investigators found that raising PaCO2 over the 
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normal range by adjusting RR and TV was feasible 34. In accordance with the results 
of this trial that was published during the patient recruitment of the current study, 
we found that targeting a very narrow range of PaCO2 near the lower or upper 
limit of the normal range by adjusting RR and TV was possible and the separa-
tion between the low-normal and high-normal PaCO2 groups was even better than 
expected. The use of continuous EtCO2 monitoring and calculating the gap between 
EtCO2 and PaCO2 each time an ABG analysis was obtained was probably crucial in 
succeeding in such a tight PaCO2 control. In the beginning of the intervention PaCO2 
was changing substantially in most patients even when MV was kept constant, and 
frequent ABG samples were needed to keep the PaCO2 in the target range. This can 
be explained by the gradual opening of the atelectasis possibly formed during CPR, 
and the following changes in dead space ventilation and ventilation-perfusion mis-
match. In addition, the haemodynamic instability seen in many patients during the 
early phase after ROSC might have contributed to the changing PaCO2. After a few 
hours the PaCO2 level stabilised in most patients, and only minimal changes in MV 
were needed to maintain it within the designated target. 
Regarding oxygen, we found that maintaining PaO2 within the target range 
by adjusting FiO2 and PEEP was feasible, and the separation between the groups 
was clear. This was not surprising as the target ranges for normoxia and moderate 
hyperoxia were substantially wider when compared with those of low-normal and 
high-normal PaCO2. Our results are in line with previous before-an-after studies 
comparing conservative versus conventional oxygen therapy in mechanically ven-
tilated patients 100,101. Importantly, in the current study, hypoxia (mean PaO2 < 8 
kPa during any 3-hour period) occurred in 11 (9%) patients, and only one of these 
patients had two 3-hour periods of hypoxia during the 36-hour intervention. There 
were no patients with severe hyperoxia (mean 3-hour PaO2 > 40 kPa) at any time 
during the intervention. 
In the current study, targeting a MAP level 65-75 mmHg or 80-100 mmHg was 
also feasible and a clear separation between the di erent blood pressure groups 
was achieved. This was somewhat expected, as goal-directed therapy aiming for a 
speci c MAP level with uids and vasoactive infusions has become routine in cir-
culatory shock patients in intensive care. Noradrenaline was the vasopressor used 
in all patients, and inotropes were needed in a much lesser extent. While the e ects 
of noradrenaline are mainly caused by its 1-stimulating activity, it also a ects CO 
in two di erent mechanisms: the increased vasoconstriction increases preload and 
thus cardiac index, and the ß1-activity slightly increases cardiac contractility 149. The 
result is a prompt raise in MAP and a moderate increase in CO without a signi cant 
raise in heart rate. In addition, noradrenaline decreases the need for volume replace-
ment, helping to avoid excessive uid administration with all its adverse e ects. In 
accordance with a previous analysis of Finnish OHCA patients 87, the signi cantly 
higher dose of noradrenaline in the high-normal MAP group in the current study 
was not associated with increased risk for new-onset CA or severe arrhythmias. 
This nding was further  supported by the results of the Neuroprotect trial 146. 
Altogether, these results suggest that hypotension can be corrected, and MAP level 
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safely adjusted with a continuous infusion of noradrenaline during post-resuscita-
tion intensive care. 
Overall outcome
Overall, 68% of the patients randomised in studies II-III were alive at 30 days after 
CA, and 65% had good neurological outcome (CPC 1-2) at six months. This is a mark-
edly good result when compared with previous reports regarding OHCA patients 
both internationally and in Finland. In a systematic review and meta-analysis of 79 
studies reporting the outcomes of over 142 000 OHCA patients all over the world, 
the pooled survival rate to hospital discharge was 7.6% 150. In the FINNRESUSCI 
study, the data of all OHCA patients in southern, central and eastern Finland were 
collected over 6 months, and the overall survival to hospital discharge was 19.9% 2.
Several reasons can explain the exceptionally good recovery rate in the current 
study. First, our study population was relatively selected as only patients with wit-
nessed arrest, shockable initial rhythm and presumed cardiac origin were included. In 
addition, patients with ROSC over 45 min or age older than 80 years were excluded. 
To compare, in the FINNRESUSCI study, 45% of patients with bystander-witnessed 
arrest with shockable initial rhythm and presumed cardiac origin survived to hospi-
tal discharge 2. Second, despite the multicentre design of the trial, 83 0f 120 patients 
(69%) included were admitted to Helsinki University Hospital, meaning that the 
CA probably occurred in the Helsinki metropolitan area where most patients are 
reached with short delays and there is an emergency medicine physician available 
already in the eld. In rural areas the time for emergency medicine personnel to 
reach the patient is usually substantially longer, which inevitably a ects the sur-
vival rate after OHCA. Third, the good quality of post-resuscitation intensive care 
in all centres taking part in the study may have a ected the results. This means that 
the patients were admitted directly to ICU without delays in the emergency room, 
coronary angiography and interventions were immediately available and TTM was 
promptly initiated and the delay to target temperature was kept as short as possible. 
In addition, under normal circumstances, there was a highly trained ICU nurse by 
the bedside of each patient at all times. Finally, it is likely that several other factors 
related to the patient background, resuscitation process and post-resuscitation care 
exist but remain unknown so far.
Arterial carbon dioxide tension and HIE
Carbon dioxide increases cerebral perfusion and in previous experimental studies 
with animals, it has seemed to have antioxidant and anti-in ammatory properties 
after cerebral ischaemia 151. In addition, CO2 has been shown to act as a potent anti-
convulsive agent both in animal and human experiments 27. Based on these ndings, 
it has been thought that hypercapnia might provide neuroprotection after CA by 
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helping to maintain adequate CBF, attenuating the in ammatory response caused by 
the systemic ischaemia-reperfusion injury, and decreasing the incidence of seizures. 
This hypothesis was supported by a randomised clinical trial where mild hypercap-
nia after CA and resuscitation reduced NSE concentrations and showed no evidence 
of harm when compared to normocapnia 34.
In the current study, we compared the e ect of low-normal and high-normal 
PaCO2 on biomarkers of cerebral and myocardial injury, cerebral oxygenation, epi-
leptic activity, and neurological outcome. We found that targeting a very narrow 
range of PaCO2 in mechanically ventilated patients was feasible, but it did not a ect 
the severity of the developing HIE, as assessed by NSE concentrations during 24-72 
h after CA or neurological recovery at 6 months. The EEG ndings were also com-
parable with both investigated PaCO2 levels. This was in contrast with some of the 
previous studies and also with our own hypothesis, but in line with a recent system-
atic review and meta-analysis of nine observational studies concluding that PaCO2 
has a U-shape association with survival and that both hypocapnia and hypercapnia 
can be detrimental during post-resuscitation care 40. 
There are several reasons that can explain the neutral results of the current study 
regarding PaCO2 and the extent of neurological damage. First, we compared PaCO2 
levels on both ends of the normal range, and it is possible that the absolute di erence 
in PaCO2 between the groups was not wide enough to demonstrate the possible 
impacts of higher CO2 level in our patients. Second, hypercapnia has several adverse 
e ects including increased ICP 22 and deepening acidosis 30, which are both major 
concerns in CA patients. The potential bene cial e ects of high-normal PaCO2 may 
have been counterbalanced with the adverse e ects, and thus no di erence in the 
outcome measures of the current study was seen. Third, the current study was not 
powered for mortality or neurological outcome, and it is possible that the sample 
size was too small to detect di erences in the surrogate markers of cerebral injury as 
well. Finally, it may be that the bene cial e ects of CO2 seen in experimental models 
are not reproducible in the clinical setting with real CA patients, and that the level 
of CO2 does not a ect the development of the brain damage after all.
Arterial oxygen tension and HIE
Previous experimental studies have demonstrated that exposure to very high levels 
of oxygen after CA may increase ROS production and exacerbate the developing 
brain injury 51. In several observational human studies, severe hyperoxia (PaO2 > 40 
kPa) has indeed been associated with poor outcome in resuscitated patients 53-56,58. In 
contrast, moderate hyperoxia has been associated with better long-term neurological 
recovery and improved organ function 33,57. The only randomised trial performed 
on the use of oxygen in OHCA patients before the current study compared FiO2 30% 
vs. 100% immediately after ROSC. Although there was no statistically signi cant dif-ference in NSE between the groups overall, the investigators saw an increase in NSE 
within a subgroup of patients exposed to 100% oxygen and not treated with TTM at 
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33 °C, suggesting a protective e ect of hypothermia against the detrimental e ects 
of hyperoxia exposure 52.
In the current study, we investigated the e ect of normoxia vs. moderate hyper-
oxia on biomarkers of cerebral injury and several other outcomes after CA. This 
was the rst randomised clinical trial comparing two di erent levels of PaO2 during 
post-CA intensive care. We found that targeting a speci c level of PaO2 was fea-
sible, but it did not a ect NSE, S100B, or TnT concentrations, epileptic activity, 
or neurological outcome at 6 months. These ndings suggest that moderate hyper-
oxia does not markedly a ect the development of HIE as compared with normoxia. 
Importantly, we did not observe any signs of harm associated with moderate hyper-
oxia in OHCA patients.
Previous studies have observed a decrease in CBF and an increase in oxygen 
extraction soon after ROSC 152,153. Based on these ndings, it would be reasonable 
to think that increasing the oxygen content of the blood in CA patients could help 
to maintain adequate oxygen delivery to the injured brain and thus to avoid cere-
bral hypoxia during the phase of hypoperfusion. Indeed, a prospective observational 
study of Finnish OHCA patients suggested that the PaO2 associated with the lowest 
mortality was around 20 kPa 33.
In the current study we found that cerebral oxygenation, as assessed with fron-
tal rSO2, was increased in the group targeting moderate hyperoxia, indicating that 
the oxygen delivery to the brain was increased with higher PaO2. However, this 
did not a ect the biomarkers of HIE or neurological outcome. The pathogenesis 
of HIE is likely to be complex, and the outcomes of CA patients can probably not 
be improved simply by increasing the oxygen delivery to the brain. The damaged 
neurons may not be able to utilize all the available oxygen e ciently, as has been 
shown to happen in patients with sepsis 154. Some of the mechanisms leading to HIE 
are caused by ischemia-reperfusion damage and increased production of ROS rather 
than hypoperfusion 13, suggesting that increasing cerebral oxygenation may have its 
drawbacks. Although the current study did not show evidence of harm related to 
moderate hyperoxia, larger trials are needed before de nitive conclusions regarding 
safe PaO2 range during post-resuscitation care can be drawn.
Blood pressure level and HIE
As mentioned above, cerebral perfusion is decreased and the autoregulation of CBF 
is often impaired after CA and successful resuscitation. This means that the MAP 
range where cerebral autoregulation remains functional is narrowed and right-
shifted 136. The injured brain becomes vulnerable to systemic hypotension, and in 
order to maintain adequate cerebral perfusion, high enough MAP becomes essential. 
Because of the lack of high-quality data, this minimum blood pressure threshold is 
unknown, and the current European guidelines do not give any speci c target level 
for MAP after CA. Instead, they recommend aiming for an adequate urine output (1 
ml/kg/h) and normal or decreasing plasma lactate levels 15.
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In previous observational studies, low arterial pressure during the early post-re-
suscitation period has been consistently associated with increased mortality and poor 
neurological outcome 78-91. However, it has been unclear whether supporting the 
circulation with vasoactive agents could optimize cerebral perfusion and improve 
outcomes, or whether the patients with severe hemodynamic instability and need 
for high vasopressor support represent a subgroup of patients with longer pre-hos-
pital no- ow times and therefore a worse prognosis per se. In addition, vasoactive 
agents and inotropes have many potential adverse e ects, and in some studies, their 
increased use after CA has been associated with poor outcome 81 86. 
The current study was the rst randomised clinical trial comparing the e ects 
of targeting two di erent levels of MAP on biomarkers of brain injury, brain oxy-
genation, epileptic activity, and neurological outcome in patients resuscitated after 
CA. Targeting a higher blood pressure level (MAP 80-100 mmHg) using vasoactive 
infusions was feasible, but it did not a ect any of the pre-de ned outcomes as com-
pared with a lower blood pressure level (MAP 65-75 mmHg). These ndings do 
not support aiming for higher blood pressure levels in comatose CA patients in an 
attempt to attenuate the developing brain damage. On the other hand, we did not 
observe any adverse e ects related to the increased vasopressor load in the higher 
MAP group, which was in accordance with a recent high-resolution observational 
study of the Finnish ICUs 87.
Our results have been supported by the Neuroprotect study, another randomised 
clinical trial comparing MAP 85-100 mmHg with the conventional MAP 65 mmHg 
level in post-CA patients, published soon after the COMACARE trial 146. The authors 
reported an increase of cerebral oxygenation in the higher MAP group, but in line 
with the current study, there was no di erence in NSE or neurological outcome 
between the groups. Moreover, there was no di erence in the di usion weighted 
MRI results, which was the primary outcome of the Neuroprotect study. In contrast 
with the COMACARE trial, the Neuroprotect trial included patients with all initial 
rhythms and thus the overall proportion of patients with good neurological out-
come (CPC 1-2) was signi cantly smaller (39% vs. 65%). 
Although the results of both COMACARE and Neuroprotect studies endorse the 
view that additional vasopressor support to target a higher MAP level higher than 
the conventional 65 mmHg may not be e ective in attenuating HIE, they are still 
far from conclusive for several reasons. First, both trials were relatively small pilot 
studies not powered to detect di erences in outcome measures such as long-term 
neurological recovery or mortality. It is possible that the sample size calculation in 
study II was too optimistic, and the studied population was too small to detect di er-
ences in NSE as well. A larger randomised trial comparing di erent blood pressure 
levels is warranted before de nitive conclusions on the bene t or harm of target-
ing higher MAP after OHCA can be drawn. Second, there is wide variation in the 
cerebrovascular haemodynamics and cerebral autoregulatory thresholds between 
patients, depending on the extent of the pre-hospital ischaemic insult, age, and pre-
vious hypertensive status. Thus, it might be that universal hemodynamic targets 
adequate for all patients cannot be found, and individual goals should be sought 
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instead. In some patients, the baseline brain damage might be too extensive to allow 
them to bene t from any intervention and on the other hand, some patients may 
recover well regardless of the targeted blood pressure level during ICU care. The 
challenge is to nd the patients most likely to bene t from hemodynamic interven-
tions and to develop a way to determine the optimal blood pressure level for each 
patient.
Cerebral oxygenation
Cerebral oxygenation is thought to re ect CBF, and moderate correlation between 
frontal rSO2 and cerebral perfusion pressure has been found in previous studies 155. 
Optimising the oxygenation and perfusion of the brain is one of the main goals of 
post-resuscitation care, and it has been thought that the information provided by 
NIRS could provide a feasible target for goal-directed therapy after CA. The prom-
ising results of frontal rSO2 monitoring in di erent perioperative settings 130 and in 
predicting ROSC during CPR 131 have further increased the expectations regarding 
its usefulness with resuscitated patients. However, the signi cance of optimising 
frontal rSO2, cerebral perfusion pressure, and CBF to improve outcomes during 
post-resuscitation care remains unde ned. 
The current study was the largest cohort of post-CA patients with continuous 
NIRS monitoring analysed so far. We found that in this relatively selected popula-
tion of OHCA patients with shockable initial rhythms, frontal rSO2 during the rst 
36 h of intensive care was not associated with NSE or neurological outcome. Our 
results do not support the hypothesis that the outcome of OHCA patients could be 
improved by goal-directed therapy targeting a speci c frontal rSO2 level, and the 
role of NIRS monitoring as part of the outcome prediction in resuscitated patients 
is questioned as well.
Our ndings contradict the results of many of the previous studies investigating 
NIRS in resusctiated CA patients 133-135. Interestingly, a striking di erence in the 
overall outcome of the patients can be seen between the studies that have reported 
a positive association between rSO2 and outcome, and those that have not. In the 
current study, 65% of patients recovered to CPC 1-2. In the two other studies where 
no clear association between frontal rSO2 and outcome could be found, the over-
all prognosis for good outcome was 47% and 54% 132,137. In contrast, in the studies 
where frontal rSO2 predicted outcome, the proportion of patients with good neu-
rological outcome varied between 4-38%. Thus, based on the results of these few 
studies with relatively small sample sizes, it seems that the ability of NIRS to predict 
outcome becomes poorer as the overall outcome of the study population improves. 
An extreme example is the Japanese study of 672 OHCA patients, where frontal rSO2 
over 42% at hospital arrival predicted good outcome with 95% speci city and 79% 
sensitivity, but the mean rSO2 was only 21% and the overall proportion of patients 
with good neurological outcome only 4% 135. Hence, if the prognostic accuracy of 
frontal rSO2 is acceptable only in situations where poor outcome is already evident 
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by conventional means, it is unlikely that NIRS monitoring would prove to be a 
useful addition in the prognostication of CA patients. 
Another problem with NIRS seems to be that even in the studies that have found 
an association between cerebral oxygenation and prognosis, there is signi cant 
overlap in the measured frontal rSO2 range between patients with good and poor 
outcome. Because of this, clear cut-o  limits have been impossible to establish. In 
addition, the absolute di erence in frontal rSO2 between patients with good and 
poor outcome has been very small in most studies, making the interpretation of 
frontal rSO2 values very di cult in the clinical setting and further compromising the 
value of NIRS monitoring in post-resuscitation care.
In the current study, high-normal PaCO2 and moderate hyperoxia after CA 
resulted in signi cantly higher rSO2 as compared with low-normal PaCO2 and 
normoxia, respectively. In contrast, higher blood pressure level did not have signif-icant e ect on cerebral oxygenation, suggesting that the autoregulation of CBF may 
remain functional even with a lower blood pressure level of 65-75 mmHg during 
the post-resuscitation period. This is in line with a previous small study where 
increasing MAP from 70 to 90 mmHg did not a ect brain tissue oxygenation 156. 
On the contrary, in the Neuroprotect trial, rSO2 was signi cantly higher in patients 
assigned to the higher MAP group and this nding was further supported with sig-
ni cantly higher cerebral perfusion in a subset of patients in whom transcranial 
Doppler measurement was performed 146. The clinical implications of these ndings 
remain unclear so far.
In a previous study assessing CBF with serial duplex ultrasound measurements 
after CA, the investigators did not nd any association between CBF and outcome 
157, which is in accordance with our ndings. However, they did nd a correlation 
between the systemic blood pressure and CBF in patients with poor outcome, sug-
gesting that impaired autoregulation of CBF during post-resuscitation care could be 
related to poor prognosis. Impaired autoregulation has been previously determined 
with the cerebral oximetry index (COx), which is a correlation coe cient between 
MAP and rSO2 158,159. Impaired autoregulation, de ned as COx > 0.3 during the rst 
24 hours after CA, has been associated with poor outcome 158. The COx has also 
been used to estimate the optimal blood pressure levels for individual patients after 
CA and, interestingly, those levels have been signi cantly higher than those recom-
mended by the current guidelines. It is possible that in the future, rSO2 monitoring 
after CA will have an important role in the assessment of CBF autoregulation, but 
interventional studies are needed to determine whether treating the blood pressure 
to the optimal target predicted by COx really improves outcomes.
Blood pressure and myocardial damage
Acute coronary occlusion is the most common cause of OHCA, and the develop-
ing myocardial infarction can lead to decreased cardiac contractility and reduced 
CO in resuscitated patients 76. Moreover, the global ischaemia–reperfusion injury 
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developing after CA and resuscitation can cause myocardial stunning and compro-
mise normal cardiac function 73. The reduced CO can lead to diastolic hypotension 
and insu cient coronary perfusion, further aggravating myocardial ischaemia and 
reducing CO even more. Eventually, this can result in a downward spiral, ending in 
multiple organ failure and cardiovascular collapse 159. In previous studies, hypoten-
sion and even low-normal blood pressure at hospital admission have been associated 
with increased mortality after AMI 160. Accordingly, the current guidelines recom-
mend using vasopressors and inotropes to maintain systemic perfusion in patients 
with AMI presenting with low MAP and severe systolic dysfunction 161.
Excessive vasopressor can increase afterload and myocardial oxygen consump-
tion, thereby aggravating the developing myocardial damage 162. In addition, 
ß1-stimulating agents, such as noradrenaline and dobutamine, can also increase the 
risk of ventricular arrhythmias and new onset CA, and the increased vasoconstric-
tion may lead to impaired microcirculation and reduced oxygen delivery in various 
tissues. The optimal level of vasopressor and inotrope support that would balance 
coronary perfusion, afterload, myocardial oxygen consumption and arrhythmogenic 
risk remains unknown.
In studies II-III, the concentration of TnT was comparable in both MAP groups, 
suggesting that the extent of myocardial damage was comparable despite the dif-ferent blood pressure levels and the signi cantly higher noradrenaline load in the 
high-normal MAP group. In contrast, in the subgroup of OHCA patients with 
concurrent AMI and vasopressor dependent hypotension in study V, targeting the 
higher MAP level of 80/85-100 mmHg was associated with a 27% reduction in myo-
cardial damage as assessed with the area under the 72-hour TnT curve. Although 
cardiac troponin is not the golden standard of assessing myocardial infarct size, it has 
correlated well with SPECT and MRI ndings in previous studies 121. Importantly, 
despite the signi cantly higher vasopressor load in the higher MAP group, the risk 
for new onset ventricular arrhythmias was not increased.
The nal size of the developing myocardial infarction after a coronary occlusion 
can only be a ected by prompt restoration of adequate perfusion and oxygen deliv-
ery to the myocardium. So far, only urgent revascularisation of the culprit artery 
has been shown to improve the outcome of AMI patients with cardiogenic shock 
163. Our ndings suggest that targeting a higher blood pressure level after coronary 
intervention may help to maintain su cient perfusion in the a ected myocardium 
and to reduce the nal infarct size, providing a new therapeutic option for hypo-
tensive AMI patients. Based on these results, it seems that the bene cial e ects of 
vasopressors on diastolic blood pressure and coronary perfusion may be greater than 
their potential adverse e ects on arrhythmogenic risk, afterload, and myocardial 
oxygen consumption.
Despite the smaller myocardial damage associated with the higher blood pres-
sure level in patients included in study V, the mortality at 6 months was comparable 
between the two MAP groups. Because the cause of death was HIE in 70% of the 
patients included in the analysis, it seems logical that an intervention that was associ-
ated with a reduction in myocardial damage did not a ect mortality in this relatively 
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small sample of patients. Interestingly, 7 out of 10 patients who died because of 
early haemodynamic shock were assigned to the lower MAP group. This supports 
the hypothesis that aggressive goal directed hemodynamic resuscitation immediately 
after successful coronary revascularisation may help prevent the deathly spiral of 
cardiogenic shock described above. However, larger randomised trials are needed 
before de nitive conclusions on the possible bene ts of this strategy on long term 
outcomes can be made.
Limitations
Several limitations in the current study should be addressed. First, despite we con-
ducted a multicentre trial, most included patients (69%) were recruited at Helsinki 
University Hospital. Second, although interventions aiming at a ecting the course 
of HIE should be started as early as possible, the study interventions were started 
at the hospital after ICU admission and not during pre-hospital care. However, the 
delay between ROSC and the beginning of the interventions was reasonably short 
for most participants. Also, the strict control of PaCO2, PaO2, and MAP levels in 
the pre-hospital setting would have been challenging especially in areas where a 
pre-hospital physician is not available. Third, as PaCO2, PaO2, EtCO2, SpO2, and 
arterial pressure are routinely monitored variables in the ICU, and the ICU sta  was 
needed in targeting the designated PaCO2, PaO2 and MAP level, the study inter-
ventions could not be blinded. However, the neurologist assessing the 6-month 
neurological outcome and the neurophysiologist analysing the EEGs were blinded 
from the study group allocations.
Fourth, the small sample size, particularly the small number of patients with poor 
outcome, limits the strength of conclusions that can be drawn. The study was not 
powered to detect di erences in mortality or neurological outcome. Thus, it is pos-
sible that some bene t or harm of the studied interventions remained undetected 
and no de nitive conclusions regarding their e cacy or safety can be drawn. Fifth, 
the overall outcome in these studies was exceptionally good for an OHCA cohort. It 
should be emphasised that the studied population was positively selected regarding 
age, initial rhythm, and a presumed cardiac cause of the arrest, limiting the general-
isability of the results. Sixth, we used a four-channel technique for EEG monitoring. 
There is a risk that some focal epileptic activity may have been unnoticed. Seventh, 
the NIRS probes attached on the patients’ forehead provided information only about 
a small area of the frontal cerebral cortex, leaving other parts of the brain uncov-
ered. Some bias could have been caused to the results because of regional variation 
in rSO2. 
Eighth, we chose the NSE concentration at 48 h as the primary outcome of the 
current study because it has been well documented as a surrogate marker of HIE and 
it has an established role in the multimodal prognostication of the OHCA patients 
116. A major pitfall of NSE is that it is not entirely speci c to neurons and substantial 
amounts of the enzyme is also found in erythrocytes. Thus, even mild haemolysis 
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can increase the NSE concentration in the blood and cause bias to the results 114. In 
the current study, 463 serum samples were obtained all together for the NSE anal-
yses. In all samples taken in the Finnish centres (n = 437), haemolysis was assessed 
using the Roche haemolysis index. In seven samples (1.5%), the haemolysis index 
was over 50, corresponding to more than 500 mg of free Hb per litre, and these sam-
ples were excluded from the analyses. This same threshold has been used in previous 
studies 109. In the samples taken at the Danish centre (n = 26), the NSE concentra-
tion was analysed immediately using the same kits as in the Finnish laboratory, but 
haemolysis was not assessed. In the remaining 430 samples, there was detectable 
-
lysis index in these samples was 19.0 ± 9. The amount of the moderately haemolytic 
samples was comparable in all the intervention groups and the main ndings of the 
study remained unchanged even when all samples with detectable haemolysis were 
excluded from the analyses.
Regarding study IV, the design was conceived post hoc and it was not included 
in the original study protocol. In addition, the study was based on measurements 
of rSO2, which is a surrogate indicator of CBF. Assessment of transcranial Doppler 
ultrasound, a direct measurement of blood ow in cerebral arteries, could have pro-
vided additional information. 
Regarding study V, we used TnT to assess myocardial infarct size although MRI 
is the current golden standard. Cardiac MRI was not part of the original protocols 
of the COMACARE or Neuroprotect studies, and for practical reasons, it would 
have been di cult to implement for intubated and mechanically ventilated patients. 
Moreover, MRI would not have been feasible nor safe for the patients with the larg-
est infarcts and haemodynamic shock, and some of these patients would have died 
before the MRI, causing bias to the results. Although the area under the 72-hour 
TnT curve has correlated well with the infarct size assessed with MRI or PET in 
previous studies 121,122, TnT is still a surrogate marker of myocardial damage and 
there are factors that can a ect its level regardless of cardiac ischaemia. For example, 
renal insu ciency or chest compressions during CPR can be the reason for elevated 
TnT levels in resuscitated patients without AMI 124,126, and both of these factors are 
potential sources of bias in our results. Nevertheless, baseline TnT levels and daily 
creatinine values during the 72-hour study period were well balanced between the 
groups.
In addition, the universal de nitions for AMI had to be adapted in study V. 
Because the patients had to be unconscious for inclusion, chest pain could not be 
assessed. Moreover, because virtually all resuscitated patients have some form of 
ECG abnormalities and rise of the troponins, these criteria could not be used either. 
Similarly, previous shock de nitions for cardiogenic shock include signs of end-or-
gan hypoperfusion such as altered mental status, cold skin, increased lactate level 
and decreased urine output that are not applicable in intubated post-CA patients 
with hypothermia induced cold diuresis and consistently elevated lactate levels 
upon admission. However, we feel that the de nitions for AMI and vasopressor 
dependent hypotension used in this study provided the most robust data possible in 
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this setting. Also, routine echocardiographic assessment was not performed for all 
patients. This could have provided additional information about myocardial contrac-
tility and CO in the di erent MAP groups. Additionally, the intervention protocol 
to target the designated MAP level was slightly di erent between the COMACARE 
and Neuroprotect studies. However, the TnT levels were very consistent across both 
trials, suggesting that the observed di erence in the extent of myocardial damage 
was more related to the MAP target than to the combination of the drugs used. Finally, because the design of study V was conceived post hoc, its results should 




The present study investigated the feasibility of targeting di erent PaCO2, PaO2, 
and MAP levels in comatose OHCA patients after successful resuscitation; the e ect 
of these interventions on the extent of the developing neurological and myocardial 
damage, cerebral oxygenation, and epileptic activity; and the association between 
cerebral oxygenation and the extent of the developing neurological damage. 
Following conclusions can be drawn:
1. Targeting low-normal or high-normal PaCO2, normoxia or moderate hyper-
oxia, and low-normal or high-normal MAP is feasible in comatose patients 
after OHCA. With frequent ABG analyses and adjustments of MV on the 
ventilator, PaCO2 can be kept within a very narrow range as targeted, and 
the oxygenation of blood can be regulated with adjustments on FiO2 and 
PEEP level. Hypotension can be corrected, and MAP level can be accurately 
controlled with a continuous infusion of noradrenaline without signi cant 
adverse e ects. Based on these results, conducting a full-scale randomised 
trial investigating the e ect of di erent PaCO2, PaO2, and MAP levels after 
CA seems feasible.
2. Targeting high-normal PaCO2, moderate hyperoxia, or high normal MAP 
after resuscitation from OHCA had no e ect on the investigated markers 
of brain injury or epileptic activity, as compared with targeting low-normal 
PaCO2, normoxia, and low-normal MAP, respectively. Higher PaCO2 and 
moderate hyperoxia increased cerebral oxygenation but MAP level did not 
a ect it. Because of the pilot nature and small sample size of the study, de ni-
tive conclusions regarding the e cacy or safety of these interventions cannot 
be drawn.
In OHCA patients with concurrent AMI and hypotension, higher MAP 
level was associated with smaller myocardial injury. Due to the small sample 
size and the post hoc design of the analysis, this result should be interpreted 
with caution and seen as hypothesis generating. Further studies are needed 
to ascertain the e ect of MAP level on the developing myocardial injury in 
AMI patients.
3. Cerebral oxygenation was not associated with the severity of neurological 
damage or neurological outcome. This nding questions the bene t of rou-
tine NIRS-monitoring in resuscitated patients.
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Future perspectives
The neutral ndings between low-normal and high-normal PaCO2 in the current 
study do not encourage performing a larger trial with the same PaCO2 targets in 
the future. However, more information about the possible neuroprotective e ects 
of hypercapnia is needed. A large randomised trial (Targeted Therapeutic Mild 
Hypercapnia After Resuscitated Cardiac Arrest [TAME], NCT03114033) compar-
ing mild hypercapnia (6.7-7.3 kPa) with normocapnia has already been initiated, 
and hopefully it will provide some answers on this matter in the near future. Future 
research should focus on further elucidating the neuroprotective mechanisms of 
CO2, and de ning the optimal target level of PaCO2 that would balance the bene ts 
and the known adverse e ects of increased ICP, acidosis and myocardial impairment.
What comes to oxygen, the ndings of the current study support the view that 
moderate hyperoxia is not harmful for OHCA patients. However, the possible bene-
cial or detrimental e ects of the increased oxygen delivery on the recovering brain 
and patient outcomes remain unclear. There is a great need for large clinical trials 
studying the long-term e ects of di erent oxygen targets in CA patients, and the 
results of the current study support the feasibility and safety of such a trial. The 
results of the Reduction of Oxygen After Cardiac Arrest (EXACT, NCT03138005) 
trial comparing SpO2 98-100% target with SpO2 90-94% target after OHCA will pro-
vide some insight to this matter in the future. Unfortunately, the interventions of 
the EXACT trial are limited to the pre-hospital phase only, and new trials extending 
the intervention time to the rst days of intensive care are required to de ne the 
optimal PaO2 target after OHCA.
The current study was the rst randomised trial assessing the e ects of di er-
ent blood pressure targets in resuscitated patients. Unfortunately, the small sample 
size limits the strength of conclusions that can be made, and larger trials powered 
to detect di erences in mortality and long-term neurological outcome are needed 
to better understand the e ects of di erent MAP levels after OHCA. The optimal 
blood pressure level is likely to be di erent between patients, depending on their 
background and baseline comorbidities. Thus, instead of applying a ‘one-size- ts-
all’ haemodynamic strategy for everyone, future research should focus on bedside 
assessment of CBF autoregulation and nding personalised perfusion targets for 
each patient.
As for NIRS, our results do not support the hypothesis that the outcome of 
OHCA patients could be improved by targeting a speci c frontal rSO2 level during 
the post-resuscitation care. In addition, our results do not support using NIRS mon-
itoring as part of the multi-modal outcome prediction after CA, questioning the 
role of routine NIRS monitoring in these patients. However, NIRS may have an 
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important role in the assessment of autoregulation of CBF and in de ning individ-
ual blood pressure targets for di erent patients. Additional analyses of the current 
trial focusing on this matter have already been started 164, and more studies should 
be planned in the future. An interesting approach to the individual blood pressure 
targets would be to predict the optimal blood pressure for each patient using NIRS 
and the COx, and to randomise patients to hourly optimised versus conventional 
blood pressure targets accordingly. Unfortunately, this kind of trial would be techni-
cally challenging and might prove to be too complicated to put into practice in most 
ICUs, limiting the size of the study.
As mentioned before, interventions aiming at attenuating the developing brain 
injury after OHCA should be started as early as possible. In the current study, the 
designated PaCO2, PaO2, and MAP levels were targeted immediately after ICU 
admission, but even this may be too late as the delay from ROSC to hospital can 
sometimes be hours. Optimising ventilatory targets and haemodynamic support 
already in the eld could be pivotal in preventing the developing cascade of cerebral 
vasoconstriction, hypoxia, and HIE during the rst hours after ROSC. Targeting 
a speci c narrow range of PaCO2, PaO2, and MAP in the pre-hospital setting is 
challenging, however, and would require a physician with the equipment for ABG 
analysis on-site. In Finland, this is currently possible around the major cities with an 
EMS doctor unit available within a relatively short distance. In these areas, a small 
pilot study comparing the timing of the interventions (immediately after ROSC vs. 
ICU admission) should be feasible and could show the way for larger trials in the 
future.
The results of study V justify a larger randomised clinical trial to de ne the opti-
mal dosage of pharmacological support in AMI patients with vasopressor dependent 
hypotension and with or without preceding CA. In addition to myocardial damage, 
this new trial should also assess di erences in coronary perfusion and cardiac 
metabolites.
In addition to de ning the optimal PaCO2, PaO2, and MAP targets, there are 
several other post-ROSC interventions that need further investigation in the near 
future. For example, the role of routine coronary angiography in improving out-
comes after OHCA should be de ned. Moreover, the e ects of xenon on mortality 
and neurological outcome should be assessed in an adequately powered randomised 
trial. The control of seizures with antiepileptic drugs is another pressing topic in 
the eld of post-resuscitation care. Finally, future studies should focus on nding 
new, more accurate biomarkers for the prognostication of resuscitated patients. 
Fortunately, some potential candidates have already been introduced, neuro lament 
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